FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

STEVEN ROSENBERG

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Living Beings

Procedures

Physiology

Co-author Network

Publications

TOP 3
L Zhang; Pawel Muranski; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Z Yu; Richard A Morgan
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Shigui Zhu; STEVEN ROSENBERG; Benoit J Van den Eynde; Pierre G Coulie; Mona El-Gamil; Yong F Li; Paul F Robbins
Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Alena Gros; Mojgan Ahmadzadeh; Mark E Dudley; Simon Turcotte; John R Wunderlich; STEVEN ROSENBERG
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of STEVEN ROSENBERG (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: L Zhang; Pawel Muranski; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Z Yu; Richard A Morgan
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Gene therapy 2013;20(5):575-80.
2012: Shigui Zhu; STEVEN ROSENBERG; Benoit J Van den Eynde; Pierre G Coulie; Mona El-Gamil; Yong F Li; Paul F Robbins
Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(9):680-8.
2012: Alena Gros; Mojgan Ahmadzadeh; Mark E Dudley; Simon Turcotte; John R Wunderlich; STEVEN ROSENBERG
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(19):5212-23.
2012: Richard A Morgan; Elizabeth A Reap; Nachimuthu Chinnasamy; Jeremy L Davis; Steven A Feldman; Howard A Fine; Laura A Johnson; Chien-Tsun Kuan; Hua Song; Kevin D Woolard; Wei Zhang; Zhili Zheng; STEVEN ROSENBERG
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Human gene therapy 2012;23(10):1043-53.
2012: Bradley J Seaman; Carter Van Waes; James C Yang; Christopher K Zalewski; Carmen C Brewer; Mark E Dudley; Elizabeth A Guardiani; Kelly A King; Richard A Morgan; STEVEN ROSENBERG; Susan Rudy; H Jeffrey Kim
Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2012;147(4):744-9.
2012: Anran Wang; Tamara Aghamolla; Melissa M Alvarez-Downing; Smita Chandran; Yu Chiu; Mark E Dudley; Chyi-Chia Richard Lee; Thomas Li; Biman C Paria; Nicholas P Restifo; STEVEN ROSENBERG; Syed A Shah; Sanmeet Singh; Udai S Kammula
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Science translational medicine 2012;4(149):149ra120.
2012: Cristina Bergamaschi; Elena Chertova; Barbara K Felber; Candido Alicea; Rachel Kelly Beach; Jenifer Bear; Margherita Rosati; STEVEN ROSENBERG; Raymond Sowder; George Pavlakis
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.
Blood 2012;120(1):e1-8.
2012: Carl June; STEVEN ROSENBERG; Michel Sadelain; Jeffrey S Weber
T-cell therapy at the threshold.
Nature biotechnology 2012;30(7):611-4.
2012: Xin Yao; STEVEN ROSENBERG; David S Schrump; Seth M Steinberg; Mojgan Ahmadzadeh; Mark E Dudley; David J Liewehr; Fang Liu; Yong-Chen Lu; Paul F Robbins
Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
Blood 2012;119(24):5688-96.
2012: Vincent T DeVita; STEVEN ROSENBERG
Two hundred years of cancer research.
The New England journal of medicine 2012;366(23):2207-14.
2012: Ling Zhang; Zhili Zheng; Azam V Nahvi; STEVEN ROSENBERG; Hui Xu; Nachimuthu Chinnasamy; Mark E Dudley; Steven A Feldman; Richard A Morgan
Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(5):430-9.
2012: Kevin M Friedman; Colin A Gross; Peter A Prieto; STEVEN ROSENBERG; John R Wunderlich; James C Yang; Laura E Devillier; Mark E Dudley
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(5):400-8.
2012: Jin-Ping Lai; Phyu Phyu Aung; Markku M Miettinen; Mark Raffeld; Paul F Robbins; STEVEN ROSENBERG; Maria Tsokos; Chyi-Chia Richard Lee
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25(6):854-8.
2012: Shicheng Yang; Daniela Bischof; Mary A Black; Kenneth Cornetta; Stephanie L Goff; Neel K Karne; Richard A Morgan; STEVEN ROSENBERG; Hui Xu; Steven A Feldman
A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes.
Human gene therapy methods 2012;23(2):73-83.
2012: Nicholas P Restifo; Mark E Dudley; STEVEN ROSENBERG
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nature reviews. Immunology 2012;12(4):269-81.
2012: Jianjian Jin; Mark E Dudley; Marianna Sabatino; Robert Somerville; David F Stroncek; John R Wilson; STEVEN ROSENBERG
Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(3):283-92.
2012: Peter A Prieto; STEVEN ROSENBERG; Richard M Sherry; Donald E White; James C Yang; Marybeth S Hughes; Udai S Kammula; Catherine L Levy; Giao Q Phan
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(7):2039-47.
2012: STEVEN ROSENBERG
Raising the bar: the curative potential of human cancer immunotherapy.
Science translational medicine 2012;4(127):127ps8.
2012: James N Kochenderfer; Carolyn Laurencot; Irina Maric; Richard A Morgan; Debbie-Ann N Nathan; Giao Q Phan; Robert Carpenter; Laura Devillier; Mark E Dudley; Steven A Feldman; Marybeth S Hughes; Udai S Kammula; Richard M Sherry; David E Spaner; Maryalice Stetler-Stevenson; Wyndham H Wilson; James C Yang; STEVEN ROSENBERG
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood 2012;119(12):2709-20.
2012: Dhanalakshmi Chinnasamy; Sid P Kerkar; Richard A Morgan; Nicholas P Restifo; Zhiya Yu; Ling Zhang; STEVEN ROSENBERG
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1672-83.
2012: Adham S Bear; Gwendolyn Binder-Scholl; Kenneth Cornetta; Mark E Dudley; Steven A Feldman; Helen E Heslop; Carl H June; Richard A Morgan; Cliona M Rooney; STEVEN ROSENBERG; Sheila A Shurtleff; Gianpietro Dotti
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(2):246-9.
2012: Jared J Gartner; Jimmy C Lin; Paul S Meltzer; STEVEN ROSENBERG; Jamie K Teer; Niraj S Trivedi; Xiaomu Wei; Sean Davis; Yardena Samuels
Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma.
BMC genomics 2012;13():505.
2012: Stephen C J Parker; STEVEN ROSENBERG; Yardena Samuels; Lingyun Song; Robert L Walker; Xiaomu Wei; Paul S Meltzer; James C Mullikin; Hatice Ozel Abaan; Subramanian S Ajay; Umesh K Bhanot; Isabel Cardenas-Navia; Gregory E Crawford; Terrence S Furey; Jared Gartner; Yevgeniy Gindin; Nancy F Hansen; J Keith Killian; Elliott H Margulies
Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.
PLoS genetics 2012;8(8):e1002871.
2012: lorenzo uccellini; Ena Wang; Yingdong Zhao; STEVEN ROSENBERG; Richard Simon; Sara Tomei; Barbara Tumaini; Maria Libera Ascierto; Davide Bedognetti; Valeria De Giorgi; Mark E Dudley; Narnygerel Erdenebileg; John B Harley; Kenneth M Kaufman; Leah Kottyan; Qiuzhen Liu; Francesco M Marincola
IRF5 gene polymorphisms in melanoma.
Journal of translational medicine 2012;10():170.
2012: Melissa M Alvarez-Downing; Mark E Dudley; Suzanne M Inchauste; STEVEN ROSENBERG; Donald E White; John R Wunderlich; Udai S Kammula
Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
World journal of surgical oncology 2012;10():113.
2012: Robert P T Somerville; Laura Devillier; Maria R Parkhurst; STEVEN ROSENBERG; Mark E Dudley
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.
Journal of translational medicine 2012;10():69.
2012: David F Stroncek; Jeffrey S Miller; Gustavo Mostoslavsky; John O'Shea; Daniel J Powell; Mahendra S Rao; Nicholas P Restifo; STEVEN ROSENBERG; Carolina Berger; Martin A Cheever; Richard W Childs; Mark E Dudley; Peter Flynn; Luca Gattinoni; James R Heath; Michael Kalos; Francesco M Marincola; Cornelis J M Melief
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
Journal of translational medicine 2012;10():48.
2011: Sid P Kerkar; Anthony J Leonardi; Francesco M Marincola; Richard A Morgan; Pawel Muranski; Robert N Reger; STEVEN ROSENBERG; Giorgio Trinchieri; Ena Wang; Zhiya Yu; Dhanalakshmi Chinnasamy; Romina S Goldszmid; Nicholas P Restifo
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
The Journal of clinical investigation 2011;121(12):4746-57.
2011: James N Kochenderfer; STEVEN ROSENBERG
Chimeric antigen receptor-modified T cells in CLL.
The New England journal of medicine 2011;365(20):1937-8; author reply 1938.
2011: STEVEN ROSENBERG; James N Kochenderfer
Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(11):1928-30.
2011: Kevin M Friedman; STEVEN ROSENBERG; Laura E Devillier; Steven A Feldman; Mark E Dudley
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(9):651-61.
2011: Todd D Prickett; STEVEN ROSENBERG; Katherine Stemke-Hale; Jamie K Teer; Vijay Walia; Xiaomu Wei; Isabel Cardenas-Navia; Praveen F Cherukuri; Michael A Davies; Jared Gartner; Jeffrey E Gershenwald; Jiji Jiang; Jimmy C Lin; Elliott H Margulies; Alfredo Molinolo; Yardena Samuels
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
Nature genetics 2011;43(11):1119-26.
2011: Tristen S Park; STEVEN ROSENBERG; Richard A Morgan
Treating cancer with genetically engineered T cells.
Trends in biotechnology 2011;29(11):550-7.
2011: Maria R Parkhurst; John P Riley; Mark E Dudley; STEVEN ROSENBERG
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(19):6287-97.
2011: STEVEN ROSENBERG
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
Nature reviews. Clinical oncology 2011;8(10):577-85.
2011: David A Solomon; Jeffrey A Toretsky; Hongtao Yu; Laura A Diaz-Martinez; Abdel G Elkahloun; Joshlean Fair; Brent T Harris; C David James; Jung-Sik Kim; Taeyeon Kim; Marc Ladanyi; STEVEN ROSENBERG; Yardena Samuels; Neerav Shukla; Todd Waldman
Mutational inactivation of STAG2 causes aneuploidy in human cancer.
Science (New York, N.Y.) 2011;333(6045):1039-43.
2011: Christopher A Klebanoff; Pawel Muranski; Douglas Palmer; Zachary A Borman; Steven E Finkelstein; Luca Gattinoni; Christian S Hinrichs; Yun Ji; Sid P Kerkar; STEVEN ROSENBERG; Christopher D Scott; Nicholas P Restifo
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(16):5343-52.
2011: Alexandre Dalet; Mona El-Gamil; Ken-ichi Hanada; Yong F Li; Paul F Robbins; STEVEN ROSENBERG; Vincent Stroobant; Nathalie Vigneron; James C Yang; Benoît J Van den Eynde
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(29):E323-31.
2011: STEVEN ROSENBERG; Richard M Sherry; Seth M Steinberg; Donald E White; John R Wunderlich; James C Yang; Marybeth S Hughes; Udai S Kammula; Carolyn M Laurencot; Kathleen E Morton; Giao Q Phan; Nicholas P Restifo; Paul F Robbins; Deborah Citrin; Mark E Dudley
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4550-7.
2011: Russell R Lonser; Debbie K Song; Sungyoung Auh; Kevin Camphausen; Deborah E Citrin; Marygrace Hagan; John D Heiss; P Benjamin Kerr; Jacob Klapper; STEVEN ROSENBERG
Surgical management of melanoma brain metastases in patients treated with immunotherapy.
Journal of neurosurgery 2011;115(1):30-6.
2011: Douglas J Schwartzentruber; David H Lawson; Jon M Richards; Robert M Conry; Donald M Miller; Jonathan Treisman; Fawaz Gailani; Lee Riley; Kevin Conlon; Barbara Pockaj; Kari L Kendra; Richard L White; Rene Gonzalez; Timothy M Kuzel; Brendan Curti; Phillip D Leming; Eric D Whitman; Jai Balkissoon; Douglas S Reintgen; Howard Kaufman; Francesco M Marincola; Maria J Merino; STEVEN ROSENBERG; Peter Choyke; Don Vena; Patrick Hwu
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
The New England journal of medicine 2011;364(22):2119-27.
2011: Xiaomu Wei; Angela Moncada-Pazos; Santiago Cal; Clara Soria-Valles; Jared Gartner; Udo Rudloff; Jimmy C Lin; STEVEN ROSENBERG; Carlos López-Otín; Yardena Samuels
Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma.
Human mutation 2011;32(6):E2148-75.
2011: Hildegund C J Ertl; Carl H June; Jeffrey Kahn; STEVEN ROSENBERG; Laurence J N Cooper; Jacqueline Corrigan-Curay; Gianpietro Dotti; John Zaia; Scott E Strome
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.
Cancer research 2011;71(9):3175-81.
2011: Xiaomu Wei; Vijay Walia; Jimmy C Lin; Jamie K Teer; Todd D Prickett; Jared Gartner; Sean Davis; Katherine Stemke-Hale; Michael A Davies; Jeffrey E Gershenwald; William Robinson; Steven Robinson; STEVEN ROSENBERG; Yardena Samuels
Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
Nature genetics 2011;43(5):442-6.
2011: Jianping Huang; Qiong J Wang; Shicheng Yang; Yong F Li; Mona El-Gamil; STEVEN ROSENBERG; Paul F Robbins
Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(4):327-35.
2011: Russell C Langan; Peter A Prieto; Richard M Sherry; Daniel Zlott; John Wunderlich; Gyorgy Csako; Rene Costello; Donald E White; STEVEN ROSENBERG; James C Yang
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(4):397-402.
2011: Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; STEVEN ROSENBERG; Nicholas P Restifo
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(4):343-52.
2011: Shicheng Yang; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; STEVEN ROSENBERG; Luca Gattinoni; Richard A Morgan
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer immunology, immunotherapy : CII 2011;60(5):739-49.
2011: Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(4):751-9.
2011: Donald B Kohn; Gianpietro Dotti; Renier Brentjens; Barbara Savoldo; Michael Jensen; Laurence J N Cooper; Carl H June; STEVEN ROSENBERG; Michel Sadelain; Helen E Heslop
CARs on track in the clinic.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(3):432-8.
2011: Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee Helman; CRYSTAL MACKALL; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; STEVEN ROSENBERG
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):917-24.
2011: Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; STEVEN ROSENBERG
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(3):620-6.
2011: Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood 2011;117(3):808-14.
2011: Nachimuthu Chinnasamy; Jennifer A Wargo; Zhiya Yu; Mahadev Rao; Timothy L Frankel; John P Riley; Jenny J Hong; Maria R Parkhurst; Steven A Feldman; David S Schrump; Nicholas P Restifo; Paul F Robbins; STEVEN ROSENBERG; Richard A Morgan
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(2):685-96.
2011: Simon Turcotte; STEVEN ROSENBERG
Immunotherapy for metastatic solid cancers.
Advances in surgery 2011;45():341-60.
2011: Shicheng Yang; Fang Liu; STEVEN ROSENBERG; Qiong J Wang; Richard A Morgan
The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes.
PloS one 2011;6(7):e22560.
2011: Steven A Feldman; Stephanie L Goff; Hui Xu; Mary A Black; James N Kochenderfer; Laura A Johnson; James C Yang; Qiong Wang; Maria R Parkhurst; Scott Cross; Richard A Morgan; Kenneth Cornetta; STEVEN ROSENBERG
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.
Human gene therapy 2011;22(1):107-15.
2010: Mark E Dudley; Colin A Gross; Michelle M Langhan; Marcos R Garcia; Richard M Sherry; James C Yang; Giao Q Phan; Udai S Kammula; Marybeth S Hughes; Deborah Citrin; Nicholas P Restifo; John R Wunderlich; Peter A Prieto; Jenny J Hong; Russell C Langan; Daniel A Zlott; Kathleen E Morton; Donald E White; Carolyn M Laurencot; STEVEN ROSENBERG
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(24):6122-31.
2010: Jeremy L Davis; Marc R Theoret; Zhili Zheng; Cor H J Lamers; STEVEN ROSENBERG; Richard A Morgan
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(23):5852-61.
2010: Timothy L Frankel; William Burns; John Riley; Richard A Morgan; Jeremy L Davis; Kenichi Hanada; Martha Quezado; STEVEN ROSENBERG; Richard E Royal
Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Cancer immunology, immunotherapy : CII 2010;59(12):1757-69.
2010: Jacob A Klapper; Jeremy L Davis; R Taylor Ripley; Franz O Smith; Dao Nguyen; King F Kwong; Leandro Mercedes; Clinton D Kemp; Aarti Mathur; Donald E White; Mark E Dudley; John R Wunderlich; STEVEN ROSENBERG; David S Schrump
Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.
The Journal of thoracic and cardiovascular surgery 2010;140(6):1276-82.
2010: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; STEVEN ROSENBERG
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Blood 2010;116(20):4099-102.
2010: James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; STEVEN ROSENBERG
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Blood 2010;116(19):3875-86.
2010: Xiaomu Wei; Todd D Prickett; Cristina G Viloria; Alfredo Molinolo; Jimmy C Lin; Isabel Cardenas-Navia; Pedro Cruz; STEVEN ROSENBERG; Michael A Davies; Jeffrey E Gershenwald; Carlos López-Otín; Yardena Samuels
Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.
Molecular cancer research : MCR 2010;8(11):1513-25.
2010: Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; STEVEN ROSENBERG
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
The Journal of clinical investigation 2010;120(11):3953-68.
2010: Takashi Inozume; Ken-Ichi Hanada; Qiong J Wang; Mojgan Ahmadzadeh; John R Wunderlich; STEVEN ROSENBERG; James C Yang
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(9):956-64.
2010: STEVEN ROSENBERG
Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(10):1744-5.
2010: Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne Topalian; James C Yang; Israel Lowy; STEVEN ROSENBERG
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(8):828-33.
2010: Stephanie L Goff; Franz O Smith; Jacob A Klapper; Richard M Sherry; John R Wunderlich; Seth M Steinberg; Donald White; STEVEN ROSENBERG; Mark E Dudley; James C Yang
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(8):840-7.
2010: Jenny J Hong; STEVEN ROSENBERG; Mark E Dudley; James C Yang; Donald E White; John A Butman; Richard M Sherry
Successful treatment of melanoma brain metastases with adoptive cell therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4892-8.
2010: Stephanie L Goff; Laura A Johnson; Mary A Black; Hui Xu; Zhili Zheng; Cyrille Cohen; Richard A Morgan; STEVEN ROSENBERG; Steven A Feldman
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
Cancer immunology, immunotherapy : CII 2010;59(10):1551-60.
2010: Anusha Kalbasi; Rajeev K Shrimali; Dhanalakshmi Chinnasamy; STEVEN ROSENBERG
Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(7):672-83.
2010: Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; STEVEN ROSENBERG; Giorgio Trinchieri; Nicholas P Restifo
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer research 2010;70(17):6725-34.
2010: Swagatam Ray; Arvind Chhabra; Nitya G Chakraborty; Upendra Hegde; David I Dorsky; Thinle Chodon; Erika von Euw; Begonya Comin-Anduix; Richard C Koya; Antoni Ribas; James S Economou; STEVEN ROSENBERG; Bijay Mukherji
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Clinical immunology (Orlando, Fla.) 2010;136(3):338-47.
2010: Rajeev K Shrimali; Zhiya Yu; Marc R Theoret; Dhanalakshmi Chinnasamy; Nicholas P Restifo; STEVEN ROSENBERG
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Cancer research 2010;70(15):6171-80.
2010: Jeremy L Davis; R Taylor Ripley; Timothy L Frankel; Irina Maric; Jay N Lozier; STEVEN ROSENBERG
Paraneoplastic granulocytosis in metastatic melanoma.
Melanoma research 2010;20(4):326-9.
2010: Giselle Y Lopez; Zachary J Reitman; David Solomon; Todd Waldman; Darell D Bigner; Roger E McLendon; STEVEN ROSENBERG; Yardena Samuels; Hai Yan
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
Biochemical and biophysical research communications 2010;398(3):585-7.
2010: Richard A Morgan; Mark E Dudley; STEVEN ROSENBERG
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Cancer journal (Sudbury, Mass.) 2010;16(4):336-41.
2010: STEVEN ROSENBERG; James C Yang; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Susan L Schwarz; Kathleen E Morton; Carolyn M Laurencot; Richard M Sherry
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(6):626-9.
2010: Shicheng Yang; Mark E Dudley; STEVEN ROSENBERG; Richard A Morgan
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(6):648-58.
2010: L Isabel Cárdenas-Navia; Pedro Cruz; Jimmy C Lin; STEVEN ROSENBERG; Yardena Samuels
Novel somatic mutations in heterotrimeric G proteins in melanoma.
Cancer biology & therapy 2010;10(1):33-7.
2010: Peter A Prieto; Katherine H Durflinger; John R Wunderlich; STEVEN ROSENBERG; Mark E Dudley
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(5):547-56.
2010: Timothy L Frankel; William R Burns; Peter D Peng; Zhiya Yu; Dhanalakshmi Chinnasamy; Jennifer A Wargo; Zhili Zheng; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(11):5988-98.
2010: William R Burns; Yangbing Zhao; Timothy L Frankel; Christian S Hinrichs; Zhili Zheng; Hui Xu; Steven A Feldman; Soldano Ferrone; STEVEN ROSENBERG; Richard A Morgan
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Cancer research 2010;70(8):3027-33.
2010: Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; STEVEN ROSENBERG
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(4):843-51.
2010: Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas Palmer; Luca Gattinoni; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(1):1-7.
2010: R Taylor Ripley; Jeremy L Davis; Jacob A Klapper; Aarti Mathur; Udai S Kammula; Richard E Royal; James C Yang; Richard M Sherry; Marybeth S Hughes; Steven Libutti; Donald E White; Seth M Steinberg; Mark E Dudley; STEVEN ROSENBERG; Itzhak Avital
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Annals of surgical oncology 2010;17(1):163-70.
2009: Yangbing Zhao; Qiong J Wang; Shicheng Yang; James N Kochenderfer; Zhili Zheng; Xiaosong Zhong; Michel Sadelain; Zelig Eshhar; STEVEN ROSENBERG; Richard A Morgan
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(9):5563-74.
2009: Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; STEVEN ROSENBERG; Nicholas P Restifo
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(41):17469-74.
2009: Franz O Smith; Jacob A Klapper; John R Wunderlich; STEVEN ROSENBERG; Mark E Dudley
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(8):870-4.
2009: Stephanie L Goff; Paul F Robbins; Mona El-Gamil; STEVEN ROSENBERG
No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(8):884-5.
2009: Todd D Prickett; Neena S Agrawal; Xiaomu Wei; Kristin E Yates; Jimmy C Lin; John R Wunderlich; Julia C Cronin; Pedro Cruz; STEVEN ROSENBERG; Yardena Samuels
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Nature genetics 2009;41(10):1127-32.
2009: William R Burns; Zhili Zheng; STEVEN ROSENBERG; Richard A Morgan
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
Blood 2009;114(14):2888-99.
2009: James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; STEVEN ROSENBERG
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2009;32(7):689-702.
2009: Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; STEVEN ROSENBERG
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Blood 2009;114(8):1537-44.
2009: P D Peng; Cyrille Cohen; S Yang; C Hsu; S Jones; Yangbing Zhao; Zhili Zheng; STEVEN ROSENBERG; Richard A Morgan
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
Gene therapy 2009;16(8):1042-9.
2009: Julia C Cronin; John Wunderlich; Stacie K Loftus; Todd D Prickett; Xiaomu Wei; Katie Ridd; Swapna Vemula; Allison S Burrell; Neena S Agrawal; Jimmy C Lin; Carolyn E Banister; Phillip Buckhaults; STEVEN ROSENBERG; Boris C Bastian; William J Pavan; Yardena Samuels
Frequent mutations in the MITF pathway in melanoma.
Pigment cell & melanoma research 2009;22(4):435-44.
2009: Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; STEVEN ROSENBERG
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood 2009;114(3):535-46.
2009: Jacob A Klapper; Armen A Thomasian; Douglas M Smith; Gayle C Gorgas; John R Wunderlich; Franz O Smith; Brian S Hampson; STEVEN ROSENBERG; Mark E Dudley
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
Journal of immunological methods 2009;345(1-2):90-9.
2009: Stephanie Jones; Peter D Peng; Shicheng Yang; Cary Hsu; Cyrille Cohen; Yangbing Zhao; John Abad; Zhili Zheng; STEVEN ROSENBERG; Richard A Morgan
Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Human gene therapy 2009;20(6):630-40.
2009: Steven Yeh; Neel K Karne; Sid P Kerkar; Charles K Heller; Douglas Palmer; Laura A Johnson; Zhuqing Li; Rachel J Bishop; Wai Wong; Richard M Sherry; James C Yang; Mark E Dudley; Nicholas P Restifo; STEVEN ROSENBERG; Robert B Nussenblatt
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology 2009;116(5):981-989.e1.
2009: Lavanya H Palavalli; Todd D Prickett; John R Wunderlich; Xiaomu Wei; Allison S Burrell; Patricia Porter-Gill; Sean Davis; Chenwei Wang; Julia C Cronin; Neena S Agrawal; Jimmy C Lin; Wendy Westbroek; Shelley Hoogstraten-Miller; Alfredo A Molinolo; Patricia Fetsch; Armando C Filie; Michael O'Connell; Carolyn E Banister; Jason D Howard; Phillip Buckhaults; Ashani T Weeraratna; Lawrence C Brody; STEVEN ROSENBERG; Yardena Samuels
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.
Nature genetics 2009;41(5):518-20.
2009: STEVEN ROSENBERG; Mark E Dudley
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
Current opinion in immunology 2009;21(2):233-40.
2009: Jennifer A Wargo; Paul F Robbins; Yong Li; Yangbing Zhao; Mona El-Gamil; Diana Caragacianu; Zhili Zheng; Julie A Hong; Stephanie Downey; David S Schrump; STEVEN ROSENBERG; Richard A Morgan
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Cancer immunology, immunotherapy : CII 2009;58(3):383-94.
2009: Sid P Kerkar; Clinton D Kemp; Austin Duffy; Udai S Kammula; David S Schrump; King F Kwong; Martha Quezado; Barry R Goldspiel; Aradhana Venkatesan; Ann Berger; Melissa Walker; Mary Ann Toomey; Seth M Steinberg; Guiseppe Giaccone; STEVEN ROSENBERG; Itzhak Avital
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Trials 2009;10():121.
2009: Maria R Parkhurst; John P Riley; Paul F Robbins; Jayne Joo; Yong Li; Zhiya Yu; STEVEN ROSENBERG
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):169-80.
2008: David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; STEVEN ROSENBERG; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Cancer research 2008;68(24):10300-6.
2008: Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; STEVEN ROSENBERG
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
Blood 2008;112(13):4953-60.
2008: Andrea Boni; Pawel Muranski; Lydie Cassard; Claudia Wrzesinski; Chrystal M Paulos; Douglas Palmer; Luca Gattinoni; Christian S Hinrichs; Chi-Chao Chan; STEVEN ROSENBERG; Nicholas P Restifo
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood 2008;112(12):4746-54.
2008: Mark E Dudley; James C Yang; Richard M Sherry; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Paul F Robbins; JianPing Huang; Deborah Citrin; Susan F Leitman; John R Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen E Morton; Carolyn Laurencot; Donald E White; STEVEN ROSENBERG
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5233-9.
2008: Marc R Theoret; Cyrille Cohen; Azam V Nahvi; Lien T Ngo; Kimberly B Suri; Daniel J Powell; Mark E Dudley; Richard A Morgan; STEVEN ROSENBERG
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.
Human gene therapy 2008;19(11):1219-32.
2008: Shicheng Yang; STEVEN ROSENBERG; Richard A Morgan
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(9):830-9.
2008: S Yang; Cyrille Cohen; P D Peng; Yangbing Zhao; L Cassard; Z Yu; Zhili Zheng; S Jones; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Gene therapy 2008;15(21):1411-23.
2008: Khoi Q Tran; Juhua Zhou; Katherine H Durflinger; Michelle M Langhan; Thomas E Shelton; John R Wunderlich; Paul F Robbins; STEVEN ROSENBERG; Mark E Dudley
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):742-51.
2008: STEVEN ROSENBERG; Mark E Dudley; Nicholas P Restifo
Cancer immunotherapy.
The New England journal of medicine 2008;359(10):1072.
2008: STEVEN ROSENBERG
Overcoming obstacles to the effective immunotherapy of human cancer.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(35):12643-4.
2008: Franz O Smith; Stephanie G Downey; Jacob A Klapper; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Catherine L Levy; Donald E White; Seth M Steinberg; STEVEN ROSENBERG
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5610-8.
2008: Jacob A Klapper; Stephanie G Downey; Franz O Smith; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard M Sherry; Richard E Royal; Seth M Steinberg; STEVEN ROSENBERG
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Cancer 2008;113(2):293-301.
2008: Willemijn B Breunis; Eduardo Tarazona-Santos; Renee Chen; Maureen Kiley; STEVEN ROSENBERG; STEPHEN CHANOCK
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(6):586-90.
2008: Douglas Palmer; Chi-Chao Chan; Luca Gattinoni; Claudia Wrzesinski; Chrystal M Paulos; Christian S Hinrichs; Daniel J Powell; Christopher A Klebanoff; Steven E Finkelstein; Robert Fariss; Zhiya Yu; Robert B Nussenblatt; STEVEN ROSENBERG; Nicholas P Restifo
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(23):8061-6.
2008: Christian S Hinrichs; Rosanne Spolski; Chrystal M Paulos; Luca Gattinoni; Keith W Kerstann; Douglas Palmer; Christopher A Klebanoff; STEVEN ROSENBERG; Warren J Leonard; Nicholas P Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood 2008;111(11):5326-33.
2008: Bianca Heemskerk; Ke Liu; Mark E Dudley; Laura A Johnson; Andrew Kaiser; Stephanie Downey; Zhili Zheng; Thomas E Shelton; Kant Matsuda; Paul F Robbins; Richard A Morgan; STEVEN ROSENBERG
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Human gene therapy 2008;19(5):496-510.
2008: Paul F Robbins; Yong F Li; Mona El-Gamil; Yangbing Zhao; Jennifer A Wargo; Zhili Zheng; Hui Xu; Richard A Morgan; Steven A Feldman; Laura A Johnson; Alan D Bennett; Steven M Dunn; Tara M Mahon; Bent K Jakobsen; STEVEN ROSENBERG
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):6116-31.
2008: STEVEN ROSENBERG; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nature reviews. Cancer 2008;8(4):299-308.
2008: Daniel J Powell; Peter Attia; Victor Ghetie; John Schindler; Ellen S Vitetta; STEVEN ROSENBERG
Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(2):189-98.
2008: John D Abad; Claudia Wrzensinski; Willem W Overwijk; Moniek A De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille Cohen; Chrystal M Paulos; Douglas Palmer; John B A G Haanen; Schumacher Ton; STEVEN ROSENBERG; Nicholas P Restifo; Richard A Morgan
T-cell receptor gene therapy of established tumors in a murine melanoma model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(1):1-6.
2008: STEVEN ROSENBERG
Why perform sentinel-lymph-node biopsy in patients with melanoma?
Nature clinical practice. Oncology 2008;5(1):1.
2007: Mark E Dudley; STEVEN ROSENBERG
Adoptive cell transfer therapy.
Seminars in oncology 2007;34(6):524-31.
2007: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; STEVEN ROSENBERG
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6681-8.
2007: James C Yang; Marybeth Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; Suzanne Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Israel Lowy; Donald E White; STEVEN ROSENBERG
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):825-30.
2007: Yangbing Zhao; Alan D Bennett; Zhili Zheng; Qiong J Wang; Paul F Robbins; Lawrence Y L Yu; Yi Li; Peter Molloy; Steven M Dunn; Bent K Jakobsen; STEVEN ROSENBERG; Richard A Morgan
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(9):5845-54.
2007: Daniel J Powell; Aloisio Felipe-Silva; Maria J Merino; Mojgan Ahmadzadeh; Tamika Allen; Catherine Levy; Donald E White; Sharon A Mavroukakis; Robert J Kreitman; STEVEN ROSENBERG; Ira Pastan
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4919-28.
2007: Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; STEVEN ROSENBERG; Nicholas P Restifo
Toll-like receptors in tumor immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5280-9.
2007: STEVEN ROSENBERG
Interleukin 2 for patients with renal cancer.
Nature clinical practice. Oncology 2007;4(9):497.
2007: Chrystal M Paulos; Claudia Wrzesinski; Andrew Kaiser; Christian S Hinrichs; Marcello Chieppa; Lydie Cassard; Douglas Palmer; Andrea Boni; Pawel Muranski; Zhiya Yu; Luca Gattinoni; Paul A Antony; STEVEN ROSENBERG; Nicholas P Restifo
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
The Journal of clinical investigation 2007;117(8):2197-204.
2007: Cary Hsu; Stephanie A Jones; Cyrille Cohen; Zhili Zheng; Kimberly F Kerstann; Juhua Zhou; Paul F Robbins; Peter D Peng; Xinglei Shen; Theotonius J Gomes; Cynthia E Dunbar; David J Munroe; Claudia Stewart; Kenneth Cornetta; Danny Wangsa; Thomas Ried; STEVEN ROSENBERG; Richard A Morgan
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.
Blood 2007;109(12):5168-77.
2007: Daniel J Powell; Christiaan R de Vries; Tamika Allen; Mojgan Ahmadzadeh; STEVEN ROSENBERG
Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):438-47.
2007: Cyrille Cohen; Yong F Li; Mona El-Gamil; Paul F Robbins; STEVEN ROSENBERG; Richard A Morgan
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.
Cancer research 2007;67(8):3898-903.
2007: Mojgan Ahmadzadeh; Paul A Antony; STEVEN ROSENBERG
IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(3):294-302.
2007: Yangbing Zhao; Maria R Parkhurst; Zhili Zheng; Cyrille Cohen; John P Riley; Luca Gattinoni; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer research 2007;67(6):2425-9.
2007: Claudia Wrzesinski; Chrystal M Paulos; Luca Gattinoni; Douglas Palmer; Andrew Kaiser; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
The Journal of clinical investigation 2007;117(2):492-501.
2007: Franz O Smith; Stephanie L Goff; Jacob A Klapper; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; STEVEN ROSENBERG
Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):130.
2007: Xinglei Shen; Juhua Zhou; Karen S Hathcock; Paul Robbins; Daniel J Powell; STEVEN ROSENBERG; Richard J Hodes
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):123-9.
2006: Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah Citrin; STEVEN ROSENBERG; Richard Childs; Nicholas P Restifo
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
Nature clinical practice. Oncology 2006;3(12):668-81.
2006: Luca Gattinoni; Anju Ranganathan; Deborah R Surman; Douglas Palmer; Paul A Antony; Marc R Theoret; David M Heimann; STEVEN ROSENBERG; Nicholas P Restifo
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Blood 2006;108(12):3818-23.
2006: Michal Lotem; Yangbing Zhao; John Riley; Patrick Hwu; Richard A Morgan; STEVEN ROSENBERG; Maria R Parkhurst
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(6):616-27.
2006: Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; STEVEN ROSENBERG
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(9):6548-59.
2006: Daniel J Powell; Mark E Dudley; Katherine A Hogan; John R Wunderlich; STEVEN ROSENBERG
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(9):6527-39.
2006: Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; STEVEN ROSENBERG; Patrick Hwu
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6106-15.
2006: Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda Rogers-Freezer; Sharon A Mavroukakis; STEVEN ROSENBERG
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science (New York, N.Y.) 2006;314(5796):126-9.
2006: Amelia Grover; Grace J Kim; Gregory Lizée; Mary Tschoi; Gang Wang; John R Wunderlich; STEVEN ROSENBERG; Sam T Hwang; Patrick Hwu
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5801-8.
2006: Cyrille Cohen; Yangbing Zhao; Zhili Zheng; STEVEN ROSENBERG; Richard A Morgan
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
Cancer research 2006;66(17):8878-86.
2006: Ajay V Maker; James C Yang; Richard M Sherry; Suzanne Topalian; Udai S Kammula; Richard E Royal; Marybeth Hughes; Michael Yellin; Leah R Haworth; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Peter Attia; STEVEN ROSENBERG
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(4):455-63.
2006: Yangbing Zhao; Zhili Zheng; Hung T Khong; STEVEN ROSENBERG; Richard A Morgan
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(4):398-406.
2006: Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; STEVEN ROSENBERG; Paul F Robbins
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(12):7726-35.
2006: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; STEVEN ROSENBERG; James C Yang
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2283-9.
2006: Kimberly Shafer-Weaver; STEVEN ROSENBERG; Susan Strobl; W Gregory Alvord; Michael Baseler; Anatoli Malyguine
Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):328-35.
2006: STEVEN ROSENBERG; Claude Sportès; Mojgan Ahmadzadeh; Terry J Fry; Lien T Ngo; Susan L Schwarz; Maryalice Stetler-Stevenson; Kathleen E Morton; Sharon A Mavroukakis; Michel MORRE; Renaud Buffet; CRYSTAL MACKALL; Ronald E Gress
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):313-9.
2006: Shujuan Liu; John Riley; STEVEN ROSENBERG; Maria R Parkhurst
Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):284-93.
2006: Luca Gattinoni; Daniel J Powell; STEVEN ROSENBERG; Nicholas P Restifo
Adoptive immunotherapy for cancer: building on success.
Nature reviews. Immunology 2006;6(5):383-93.
2006: Kimberly R Lindsey; Linda Gritz; Richard M Sherry; Andrea Abati; Patricia A Fetsch; Lisa C Goldfeder; Monica I Gonzales; Kimberly A Zinnack; Linda Rogers-Freezer; Leah R Haworth; Sharon A Mavroukakis; Donald E White; Seth M Steinberg; Nicholas P Restifo; Dennis Panicali; STEVEN ROSENBERG; Suzanne Topalian
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2526-37.
2006: Martin J Romeo; John R Wunderlich; Lien T Ngo; STEVEN ROSENBERG; Seth M Steinberg; berman david
Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2463-7.
2006: Mojgan Ahmadzadeh; STEVEN ROSENBERG
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Blood 2006;107(6):2409-14.
2006: STEVEN ROSENBERG; Richard M Sherry; Kathleen E Morton; James C Yang; Suzanne Topalian; Richard E Royal; Udai S Kammula; Nicholas P Restifo; Marybeth S Hughes; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):224-31.
2006: Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; STEVEN ROSENBERG
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):208-14.
2006: Samer H Jaber; Edward W Cowen; Leah R Haworth; Susan Booher; berman david; STEVEN ROSENBERG; Sam T Hwang
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Archives of dermatology 2006;142(2):166-72.
2006: Yangbing Zhao; Zhili Zheng; Cyrille Cohen; Luca Gattinoni; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(1):151-9.
2005: Ajay V Maker; Peter Attia; STEVEN ROSENBERG
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7746-54.
2005: Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; STEVEN ROSENBERG; Richard A Morgan
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7226-34.
2005: Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; STEVEN ROSENBERG
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Annals of surgical oncology 2005;12(12):1005-16.
2005: Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; STEVEN ROSENBERG; Paul F Robbins
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(10):7046-52.
2005: STEVEN ROSENBERG; Richard M Sherry; Kathleen E Morton; William J Scharfman; James C Yang; Suzanne Topalian; Richard E Royal; Udai S Kammula; Nicholas P Restifo; Marybeth S Hughes; Douglas J Schwartzentruber; berman david; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White; Seth M Steinberg
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):6169-76.
2005: Cyrille Cohen; Zhili Zheng; Regina Bray; Yangbing Zhao; Linda A Sherman; STEVEN ROSENBERG; Richard A Morgan
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):5799-808.
2005: Joseph A Blansfield; Kimberly E Beck; Khoi Tran; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Suzanne Topalian; Leah R Haworth; Catherine Levy; STEVEN ROSENBERG; Richard M Sherry
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):593-8.
2005: Peter Attia; Ajay V Maker; Leah R Haworth; Linda Rogers-Freezer; STEVEN ROSENBERG
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):582-92.
2005: Christian S Hinrichs; Douglas Palmer; STEVEN ROSENBERG; Nicholas P Restifo
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):517-24.
2005: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; STEVEN ROSENBERG; Nicholas P Restifo
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
The Journal of experimental medicine 2005;202(7):907-12.
2005: Dara L Aisner; Ajay V Maker; STEVEN ROSENBERG; berman david
Loss of S100 antigenicity in metastatic melanoma.
Human pathology 2005;36(9):1016-9.
2005: Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha Quezado; James C Yang; Richard M Sherry; Suzanne Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoffrey Nichol; Michael Yellin; STEVEN ROSENBERG
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6043-53.
2005: Christopher A Klebanoff; Luca Gattinoni; Parizad Torabi-Parizi; Kimberly F Kerstann; Adela R Cardones; Steven E Finkelstein; Douglas Palmer; Paul A Antony; Sam T Hwang; STEVEN ROSENBERG; Thomas Waldmann; Nicholas P Restifo
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(27):9571-6.
2005: Daniel J Powell; Linda L Parker; STEVEN ROSENBERG
Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):403-11.
2005: Luca Gattinoni; Christopher A Klebanoff; Douglas Palmer; Claudia Wrzesinski; Kimberly F Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; STEVEN ROSENBERG; Nicholas P Restifo
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
The Journal of clinical investigation 2005;115(6):1616-26.
2005: STEVEN ROSENBERG
The emergence of modern cancer immunotherapy.
Annals of surgical oncology 2005;12(5):344-6.
2005: Mojgan Ahmadzadeh; STEVEN ROSENBERG
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(9):5215-23.
2005: Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; STEVEN ROSENBERG; Paul F Robbins
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(3):258-67.
2005: Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John R Wunderlich; Robert G Hawley; Morvarid Moayeri; STEVEN ROSENBERG; Richard A Morgan
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Human gene therapy 2005;16(4):457-72.
2005: Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne Topalian; Nicholas P Restifo; Richard E Royal; Udai S Kammula; Donald E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; berman david; Armando C Filie; Andrea Abati; STEVEN ROSENBERG
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2346-57.
2005: Yangbing Zhao; Zhili Zheng; Paul F Robbins; Hung T Khong; STEVEN ROSENBERG; Richard A Morgan
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(7):4415-23.
2005: STEVEN ROSENBERG
Cancer immunotherapy comes of age.
Nature clinical practice. Oncology 2005;2(3):115.
2005: Jehad Charo; Steven E Finkelstein; Navrose Grewal; Nicholas P Restifo; Paul F Robbins; STEVEN ROSENBERG
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Cancer research 2005;65(5):2001-8.
2005: Paul A Antony; Ciriaco Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; STEVEN ROSENBERG; Nicholas P Restifo
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(5):2591-601.
2005: STEVEN ROSENBERG
Cell transfer and other immunotherapeutic strategies.
Clinical advances in hematology & oncology : H&O 2005;3(1):28-9.
2005: Nicholas P Restifo; STEVEN ROSENBERG
Use of standard criteria for assessment of cancer vaccines.
The lancet oncology 2005;6(1):3-4.
2005: Juhua Zhou; Mark E Dudley; STEVEN ROSENBERG; Paul F Robbins
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(1):53-62.
2005: Daniel J Powell; Mark E Dudley; Paul F Robbins; STEVEN ROSENBERG
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Blood 2005;105(1):241-50.
2004: Juhua Zhou; Mark E Dudley; STEVEN ROSENBERG; Paul F Robbins
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(12):7622-9.
2004: Paul F Robbins; Mark E Dudley; John R Wunderlich; Mona El-Gamil; Yong F Li; Juhua Zhou; Jianping Huang; Daniel J Powell; STEVEN ROSENBERG
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(12):7125-30.
2004: Michael R Robinson; Chi-Chao Chan; James C Yang; Benjamin I Rubin; Gerald J Gracia; H Nida Sen; Karl G Csaky; STEVEN ROSENBERG
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):478-9.
2004: Hung T Khong; James C Yang; Suzanne Topalian; Richard M Sherry; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):472-7.
2004: STEVEN ROSENBERG; Mark E Dudley
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14639-45.
2004: STEVEN ROSENBERG; James C Yang; Nicholas P Restifo
Cancer immunotherapy: moving beyond current vaccines.
Nature medicine 2004;10(9):909-15.
2004: Steven E Finkelstein; Jorge Carrasquillo; John M Hoffman; Barbara Galen; Peter Choyke; Donald E White; STEVEN ROSENBERG; Richard M Sherry
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
Annals of surgical oncology 2004;11(8):731-8.
2004: Steven E Finkelstein; David M Heimann; Christopher A Klebanoff; Paul A Antony; Luca Gattinoni; Christian S Hinrichs; Leroy N Hwang; Douglas Palmer; Paul J Spiess; Deborah R Surman; Claudia Wrzesiniski; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
Journal of leukocyte biology 2004;76(2):333-7.
2004: Maria R Parkhurst; John P Riley; Takehito Igarashi; Yong Li; Paul F Robbins; STEVEN ROSENBERG
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4688-98.
2004: Dina M Elaraj; Donald E White; Seth M Steinberg; Leah R Haworth; STEVEN ROSENBERG; James C Yang
A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(4):259-64.
2004: Jianping Huang; Mona El-Gamil; Mark E Dudley; Yong F Li; STEVEN ROSENBERG; Paul F Robbins
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(10):6057-64.
2004: STEVEN ROSENBERG
Development of effective immunotherapy for the treatment of patients with cancer.
Journal of the American College of Surgeons 2004;198(5):685-96.
2004: Hung T Khong; Qiong J Wang; STEVEN ROSENBERG
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):184-90.
2004: STEVEN ROSENBERG
Shedding light on immunotherapy for cancer.
The New England journal of medicine 2004;350(14):1461-3.
2004: Maria R Parkhurst; John P Riley; Paul F Robbins; STEVEN ROSENBERG
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(2):79-91.
2004: Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas Palmer; Yutaka Tagaya; STEVEN ROSENBERG; Thomas Waldmann; Nicholas P Restifo
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(7):1969-74.
2004: Daniel J Powell; STEVEN ROSENBERG
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(1):36-47.
2003: Cristina Maccalli; Yong F Li; Mona El-Gamil; STEVEN ROSENBERG; Paul F Robbins
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Cancer research 2003;63(20):6735-43.
2003: Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; STEVEN ROSENBERG
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(6):3287-95.
2003: STEVEN ROSENBERG; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne Topalian; Nicholas P Restifo; Armando C Filie; Richard Chang; Mark E Dudley
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(5):385-93.
2003: Mark E Dudley; STEVEN ROSENBERG
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Nature reviews. Cancer 2003;3(9):666-75.
2003: Dirk Nagorsen; Monica C Panelli; Mark E Dudley; Steven E Finkelstein; STEVEN ROSENBERG; Francesco M Marincola
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Gene therapy 2003;10(20):1754-65.
2003: Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; STEVEN ROSENBERG; Nicholas P Restifo
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
The Journal of experimental medicine 2003;198(4):569-80.
2003: James C Yang; Richard M Sherry; Seth M Steinberg; Suzanne Topalian; Douglas J Schwartzentruber; Patrick Hwu; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Donald E White; David J Liewehr; Maria J Merino; STEVEN ROSENBERG
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3127-32.
2003: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Suzanne Topalian; Richard M Sherry; Nicholas P Restifo; John R Wunderlich; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Linda Gritz; Dennis Panicali; Donald E White
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2973-80.
2003: James C Yang; Leah R Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne Topalian; Seth M Steinberg; Helen X Chen; STEVEN ROSENBERG
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
The New England journal of medicine 2003;349(5):427-34.
2003: Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; STEVEN ROSENBERG
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(14):8372-7.
2003: Giao Q Phan; Christopher E Touloukian; James C Yang; Nicholas P Restifo; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):349-56.
2003: Mark E Dudley; John R Wunderlich; Thomas E Shelton; Jos Even; STEVEN ROSENBERG
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):332-42.
2003: STEVEN ROSENBERG; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Human gene therapy 2003;14(8):709-14.
2003: Maria R Parkhurst; Cormac DePan; John P Riley; STEVEN ROSENBERG; Suyu Shu
Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(10):5317-25.
2003: J Carl Barrett; L Michelle Bennett; Laura Kay Fleming; W Marston Linehan; Lance A Liotta; STEVEN ROSENBERG; Emanuel F Petricoin; Louis M Staudt; Tracy E Thompson; James C Yang
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Clinical advances in hematology & oncology : H&O 2003;1(5):302-6.
2003: Ke Liu; STEVEN ROSENBERG
Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):190-201.
2003: John P Riley; STEVEN ROSENBERG; Maria R Parkhurst
Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Journal of immunological methods 2003;276(1-2):103-19.
2003: David M Heimann; STEVEN ROSENBERG
Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(2):179-80.
2003: Peter Attia; Giao Q Phan; Paul H Duray; STEVEN ROSENBERG
Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.
American journal of clinical oncology 2003;26(1):42-5.
2003: Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; STEVEN ROSENBERG; Nicholas P Restifo
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(3):1579-85.
2003: Luv Ram Javia; STEVEN ROSENBERG
CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(1):85-93.
2002: Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; STEVEN ROSENBERG
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(10):6036-47.
2002: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne Topalian; Richard M Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul H Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science (New York, N.Y.) 2002;298(5594):850-4.
2002: Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Réjean Lapointe; Patrick Hwu; STEVEN ROSENBERG; Nicholas P Restifo
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
Cancer research 2002;62(18):5144-7.
2002: Gang Zeng; Yong Li; Mona El-Gamil; John Sidney; Alexandro Sette; Rongfu Wang; STEVEN ROSENBERG; Paul F Robbins
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Cancer research 2002;62(13):3630-5.
2002: Ena Wang; Lance D Miller; Galen A Ohnmacht; Simone Mocellin; Ainhoa Perez-Diez; David Petersen; Yingdong Zhao; Richard Simon; John I Powell; Esther Asaki; H Richard Alexander; Paul H Duray; Meenhard Herlyn; Nicholas P Restifo; Edison Liu; STEVEN ROSENBERG; Francesco M Marincola
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer research 2002;62(13):3581-6.
2002: Hung T Khong; STEVEN ROSENBERG
The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
Cancer research 2002;62(11):3020-3.
2002: Vladia Monsurrò; Dirk Nagorsen; Ena Wang; Maurizio Provenzano; Mark E Dudley; STEVEN ROSENBERG; Francesco M Marincola
Functional heterogeneity of vaccine-induced CD8(+) T cells.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(11):5933-42.
2002: Carlos E Marroquin; Jennifer A Westwood; Réjean Lapointe; Arnold Mixon; John R Wunderlich; Dania Caron; STEVEN ROSENBERG; Patrick Hwu
Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):278-88.
2002: Simone Seiter; vladia monsurro; Mai-Britt Nielsen; Ena Wang; Maurizio Provenzano; John R Wunderlich; STEVEN ROSENBERG; Francesco M Marincola
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):252-63.
2002: Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):243-51.
2002: STEVEN ROSENBERG; Paul J Spiess; David E Kleiner
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):218-25.
2002: David M Weinreich; STEVEN ROSENBERG
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(2):185-7.
2002: STEVEN ROSENBERG; Panida Tong-On; Yong Li; John P Riley; Mona El-Gamil; Maria R Parkhurst; Paul F Robbins
Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(5):2402-7.
2002: Hung T Khong; STEVEN ROSENBERG
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(2):951-6.
2002: Lisa M Guirguis; James C Yang; Donald E White; Seth M Steinberg; David J Liewehr; STEVEN ROSENBERG; Douglas J Schwartzentruber
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):82-7.
2002: Stacy E Thurber; Hung T Khong; Udai S Kammula; STEVEN ROSENBERG
Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):63-71.
2002: Mark D McKee; Stacey A Cecco; Julie E Niemela; Janice Cormier; Christina J Kim; Seth M Steinberg; Nadja N Rehak; Ronald J Elin; STEVEN ROSENBERG
Effects of interleukin 2 therapy on lymphocyte magnesium levels.
The Journal of laboratory and clinical medicine 2002;139(1):5-12.
2002: John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia A Seipp; Leah R Haworth; Sharon A Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; STEVEN ROSENBERG
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):142-52.
2001: STEVEN ROSENBERG
Progress in the development of immunotherapy for the treatment of patients with cancer.
Journal of internal medicine 2001;250(6):462-75.
2001: Kebin Liu; STEVEN ROSENBERG
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(11):6356-65.
2001: Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
Cancer research 2001;61(22):8100-4.
2001: STEVEN ROSENBERG
Cellular therapy: an introduction.
Cancer journal (Sudbury, Mass.) 2001;7 Suppl 2():S51-2.
2001: Simone Mocellin; Patricia A Fetsch; Andrea Abati; Giao Q Phan; Ena Wang; Maurizio Provenzano; David Stroncek; STEVEN ROSENBERG; Francesco M Marincola
Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(6):447-58.
2001: Giao Q Phan; Peter Attia; Seth M Steinberg; Donald E White; STEVEN ROSENBERG
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3477-82.
2001: Galen A Ohnmacht; Ena Wang; Simone Mocellin; Andrea Abati; Armando C Filie; Patricia A Fetsch; AI Riker; Udai S Kammula; STEVEN ROSENBERG; Francesco M Marincola
Short-term kinetics of tumor antigen expression in response to vaccination.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(3):1809-20.
2001: Mark E Dudley; John R Wunderlich; Michael I Nishimura; D Yu; James C Yang; Suzanne Topalian; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Richard M Sherry; Susan F Leitman; STEVEN ROSENBERG
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(4):363-73.
2001: Mine Harada; Yong F Li; Mona El-Gamil; G A Ohnmacht; STEVEN ROSENBERG; Paul F Robbins
Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(4):323-33.
2001: James R Vasselli; JC Yang; W Marston Linehan; D E White; STEVEN ROSENBERG; McClellan Walther
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
The Journal of urology 2001;166(1):68-72.
2001: STEVEN ROSENBERG
Progress in human tumour immunology and immunotherapy.
Nature 2001;411(6835):380-4.
2001: John P Riley; STEVEN ROSENBERG; Maria R Parkhurst
Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):212-20.
2001: Vladia Monsurrò; Mai-Britt Nielsen; Ainhoa Perez-Diez; Mark E Dudley; Ena Wang; STEVEN ROSENBERG; Francesco M Marincola
Kinetics of TCR use in response to repeated epitope-specific immunization.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(9):5817-25.
2001: Gang Zeng; X Wang; Paul F Robbins; STEVEN ROSENBERG; Rongfu Wang
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(7):3964-9.
2001: Galen A Ohnmacht; Giao Q Phan; Sharon A Mavroukakis; Seth M Steinberg; Yvonne R Shea; Frank G Witebsky; L S McIntyre; R S Goodwin; Paula M Muehlbauer; Kathleen E Morton; Linda Rogers-Freezer; Claudia A Seipp; STEVEN ROSENBERG; Francesco M Marincola
A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(2):188-92.
2001: Todd S Weiser; Z Sheng Guo; Galen A Ohnmacht; M L Parkhurst; Panida Tong-On; Francesco M Marincola; Maria R Fischette; X Yu; G Aaron Chen; Julie A Hong; John H Stewart; Dao Nguyen; STEVEN ROSENBERG; David S Schrump
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(2):151-61.
2001: Yutaka Kawakami; X Wang; T Shofuda; H Sumimoto; J Tupesis; E Fitzgerald; STEVEN ROSENBERG
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(4):2871-7.
2001: Mine Harada; Yong F Li; Mona El-Gamil; STEVEN ROSENBERG; Paul F Robbins
Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Cancer research 2001;61(3):1089-94.
2001: E Chang; STEVEN ROSENBERG
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(1):88-90.
2001: S Bownds; Panida Tong-On; STEVEN ROSENBERG; Maria R Parkhurst
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(1):1-9.
2000: Linda L Parker; M T Do; Jennifer A Westwood; John R Wunderlich; Mark E Dudley; STEVEN ROSENBERG; Patrick Hwu
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
Human gene therapy 2000;11(17):2377-87.
2000: Michael K Fritsch; STEVEN ROSENBERG; P H Duray
Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(5):557-69.
2000: Udai S Kammula; Francesco M Marincola; STEVEN ROSENBERG
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.
Journal of the National Cancer Institute 2000;92(16):1336-44.
2000: Mai-Britt Nielsen; vladia monsurro; Stephen A Migueles; Ena Wang; Ainhoa Perez-Diez; KH Lee; Udai S Kammula; STEVEN ROSENBERG; Francesco M Marincola
Status of activation of circulating vaccine-elicited CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(4):2287-96.
2000: Gang Zeng; Christopher E Touloukian; X Wang; Nicholas P Restifo; STEVEN ROSENBERG; Rongfu Wang
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(2):1153-9.
2000: Monica C Panelli; John R Wunderlich; J Jeffries; Ena Wang; Arnold Mixon; STEVEN ROSENBERG; Francesco M Marincola
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):487-98.
2000: MD McKee; Timothy M Clay; R A Diamond; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):419-29.
2000: John H Stewart; STEVEN ROSENBERG
Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):401-4.
2000: AI Riker; Udai S Kammula; Monica C Panelli; Ena Wang; Galen A Ohnmacht; Seth M Steinberg; STEVEN ROSENBERG; Francesco M Marincola
Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 2000;86(6):818-26.
2000: STEVEN ROSENBERG
Identification of cancer antigens: impact on development of cancer immunotherapies.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 3():S200-7.
2000: C E Marroquin; Donald E White; Seth M Steinberg; STEVEN ROSENBERG; Douglas J Schwartzentruber
Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(3):387-92.
2000: Kimberly R Lindsey; STEVEN ROSENBERG; Richard M Sherry
Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1954-9.
2000: Monica C Panelli; Maria Bettinotti; K Lally; Galen A Ohnmacht; Y Li; P Robbins; AI Riker; STEVEN ROSENBERG; Francesco M Marincola
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(8):4382-92.
2000: STEVEN ROSENBERG; R. Michael Blaese; M K Brenner; A B Deisseroth; F D Ledley; M T Lotze; J M Wilson; Gary Nabel; K Cornetta; J S Economou; S M Freeman; S R Riddell; M Brenner; E Oldfield; B Gansbacher; C Dunbar; Robert E Walker; F G Schuening; J A Roth; R G Crystal; M J Welsh; K Culver; H E Heslop; J Simons; R W Wilmott; R C Boucher; H F Siegler; J A Barranger; S Karlsson; D Kohn; J E Galpin; C Raffel; Charles Hesdorffer; J Ilan; Peter A Cassileth; J O'Shaughnessy; L E Kun; T K Das; F Wong-Staal; R E Sobol; R Haubrich; M Sznol; J Rubin; E J Sorcher; Joseph D Rosenblatt; R Walker; K Brigham; N Vogelzang; E Hersh; S L Eck
Human gene marker/therapy clinical protocols.
Human gene therapy 2000;11(6):919-79.
2000: STEVEN ROSENBERG
The identification of cancer antigens: impact on the development of cancer vaccines.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S142-9.
2000: Christopher E Touloukian; Wolfgang W Leitner; Suzanne Topalian; Yong F Li; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(7):3535-42.
2000: Mark E Dudley; Lien T Ngo; Jennifer A Westwood; John R Wunderlich; STEVEN ROSENBERG
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Cancer journal (Sudbury, Mass.) 2000;6(2):69-77.
2000: Richard I Fisher; STEVEN ROSENBERG; G Fyfe
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
The cancer journal from Scientific American 2000;6 Suppl 1():S55-7.
2000: Michael B Atkins; L Kunkel; Mario Sznol; STEVEN ROSENBERG
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
The cancer journal from Scientific American 2000;6 Suppl 1():S11-4.
2000: STEVEN ROSENBERG
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
The cancer journal from Scientific American 2000;6 Suppl 1():S2-7.
2000: Andrea Ladányi; Michael I Nishimura; STEVEN ROSENBERG; James C Yang
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):36-47.
2000: Y Kawakami; N Dang; X Wang; JP Tupesis; Paul F Robbins; Rongfu Wang; John R Wunderlich; J R Yannelli; STEVEN ROSENBERG
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):17-27.
2000: Monica C Panelli; AI Riker; Udai S Kammula; Ena Wang; KH Lee; STEVEN ROSENBERG; Francesco M Marincola
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(1):495-504.
1999: Michael I Nishimura; Dody Avichezer; Mary Custer; C S Lee; Chi Chen; Maria R Parkhurst; R A Diamond; Paul F Robbins; Douglas J Schwartzentruber; STEVEN ROSENBERG
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Cancer research 1999;59(24):6230-8.
1999: Udai S Kammula; KH Lee; AI Riker; Ena Wang; Galen A Ohnmacht; STEVEN ROSENBERG; Francesco M Marincola
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6867-75.
1999: STEVEN ROSENBERG; R. Michael Blaese; M K Brenner; A B Deisseroth; F D Ledley; M T Lotze; J M Wilson; Gary Nabel; Kenneth Cornetta; J S Economou; S M Freeman; S R Riddell; E Oldfield; B Gansbacher; Cynthia Dunbar; Robert E Walker; F G Schuening; J A Roth; R G Crystal; M J Welsh; KW Culver; H E Heslop; J Simons; R W Wilmott; N A Habib
Human gene marker/therapy clinical protocols.
Human gene therapy 1999;10(18):3067-123.
1999: KH Lee; Ena Wang; Mai-Britt Nielsen; John R Wunderlich; Stephen A Migueles; Mark Connors; Seth M Steinberg; STEVEN ROSENBERG; Francesco M Marincola
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6292-300.
1999: Howard Kaufman; J B Rao; Kari R Irvine; Vincenzo Bronte; STEVEN ROSENBERG; Nicholas P Restifo; K R Irivine
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):489-96.
1999: Christopher E Touloukian; STEVEN ROSENBERG
A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute.
The cancer journal from Scientific American 1999;5(5):269-74.
1999: Rongfu Wang; STEVEN ROSENBERG
Human tumor antigens for cancer vaccine development.
Immunological reviews 1999;170():85-100.
1999: AI Riker; JN Cormier; Monica C Panelli; Udai S Kammula; Ena Wang; Andrea Abati; Patricia A Fetsch; KH Lee; S Steinberg; STEVEN ROSENBERG; Francesco M Marincola
Immune selection after antigen-specific immunotherapy of melanoma.
Surgery 1999;126(2):112-20.
1999: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Mario Sznol; Susan L Schwarz; Paul J Spiess; John R Wunderlich; Claudia A Seipp; JH Einhorn; Linda Rogers-Freezer; Donald E White
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(3):1690-5.
1999: Michael B Atkins; M T Lotze; Janice P Dutcher; Richard I Fisher; G Weiss; K Margolin; Jeffrey Abrams; Mario Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; STEVEN ROSENBERG
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2105-16.
1999: R Hurst; Donald E White; J Heiss; David Lee; STEVEN ROSENBERG; Douglas J Schwartzentruber
Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(4):356-62.
1999: Mark E Dudley; Michael I Nishimura; A K Holt; STEVEN ROSENBERG
Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(4):288-98.
1999: Timothy M Clay; Mary Custer; J Sachs; Patrick Hwu; STEVEN ROSENBERG; Michael I Nishimura
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):507-13.
1999: J R Wagner; McClellan Walther; W Marston Linehan; D E White; STEVEN ROSENBERG; JC Yang
Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
The Journal of urology 1999;162(1):43-5.
1999: Kari R Irvine; Maria R Parkhurst; EP Shulman; JP Tupesis; Mary Custer; Christopher E Touloukian; Paul F Robbins; Alicia Gómez Yafal; P Greenhalgh; R P Sutmuller; R Offringa; STEVEN ROSENBERG; Nicholas P Restifo
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
Cancer research 1999;59(11):2536-40.
1999: Rongfu Wang; X Wang; A C Atwood; Suzanne Topalian; STEVEN ROSENBERG
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.
Science (New York, N.Y.) 1999;284(5418):1351-4.
1999: Rongfu Wang; X Wang; STEVEN ROSENBERG
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.
The Journal of experimental medicine 1999;189(10):1659-68.
1999: Willem W Overwijk; David Lee; Deborah R Surman; Kari R Irvine; Christopher E Touloukian; Chi-Chao Chan; MW Carroll; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(6):2982-7.
1999: TZ Zaks; D B Chappell; STEVEN ROSENBERG; Nicholas P Restifo
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(6):3273-9.
1999: STEVEN ROSENBERG
A new era of cancer immunotherapy: converting theory to performance.
CA: a cancer journal for clinicians 1999;49(2):70-3, 65.
1999: STEVEN ROSENBERG
A new era for cancer immunotherapy based on the genes that encode cancer antigens.
Immunity 1999;10(3):281-7.
1999: C J Kim; C C Chan; STEVEN ROSENBERG
Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):182-3.
1999: MD McKee; Timothy M Clay; STEVEN ROSENBERG; Michael I Nishimura
Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):93-102.
1999: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Claudia A Seipp; JH Einhorn; Donald E White; Seth M Steinberg
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):968-75.
1999: Rembert Pieper; Robert E Christian; Monica I Gonzales; Michael I Nishimura; Ghanshyam Gupta; Robert E Settlage; Jeffrey Shabanowitz; STEVEN ROSENBERG; Donald F Hunt; Suzanne Topalian
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.
The Journal of experimental medicine 1999;189(5):757-66.
1999: Timothy M Clay; Mary Custer; MD McKee; Maria R Parkhurst; Paul F Robbins; Kimberly F Kerstann; John R Wunderlich; STEVEN ROSENBERG; Michael I Nishimura
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1749-55.
1999: Herbert J Zeh; Donna Perry-Lalley; Mark E Dudley; STEVEN ROSENBERG; James C Yang
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(2):989-94.
1999: AI Riker; Monica C Panelli; Udai S Kammula; Ena Wang; John R Wunderlich; Andrea Abati; Patricia A Fetsch; STEVEN ROSENBERG; Francesco M Marincola
Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma.
Cancer detection and prevention 1999;23(5):387-96.
1999: L Lee; Rongfu Wang; X Wang; Arnold Mixon; Bruce E Johnson; STEVEN ROSENBERG; David S Schrump
NY-ESO-1 may be a potential target for lung cancer immunotherapy.
The cancer journal from Scientific American 1999;5(1):20-5.
1999: Nicholas P Restifo; STEVEN ROSENBERG
Developing recombinant and synthetic vaccines for the treatment of melanoma.
Current opinion in oncology 1999;11(1):50-7.
1999: D B Chappell; TZ Zaks; STEVEN ROSENBERG; Nicholas P Restifo
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Cancer research 1999;59(1):59-62.
1998: STEVEN ROSENBERG; Y Zhai; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Claudia A Seipp; JH Einhorn; B Roberts; Donald E White
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Journal of the National Cancer Institute 1998;90(24):1894-900.
1998: Y Kawakami; Paul F Robbins; X Wang; JP Tupesis; Maria R Parkhurst; Xiaoqiang Kang; K Sakaguchi; Ettore Appella; STEVEN ROSENBERG
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(12):6985-92.
1998: Vincenzo Bronte; M Wang; Willem W Overwijk; Deborah R Surman; Federica Pericle; STEVEN ROSENBERG; Nicholas P Restifo
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(10):5313-20.
1998: TZ Zaks; STEVEN ROSENBERG
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Cancer research 1998;58(21):4902-8.
1998: Maria R Parkhurst; EB Fitzgerald; Scott Southwood; Alexandro Sette; STEVEN ROSENBERG; Y Kawakami
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Cancer research 1998;58(21):4895-901.
1998: KH Lee; Monica C Panelli; C J Kim; AI Riker; Maria Bettinotti; MM Roden; Patricia A Fetsch; Andrea Abati; STEVEN ROSENBERG; Francesco M Marincola
Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(8):4183-94.
1998: Rongfu Wang; S L Johnston; Gang Zeng; Suzanne Topalian; Douglas J Schwartzentruber; STEVEN ROSENBERG
A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(7):3598-606.
1998: Nicholas P Restifo; Deborah R Surman; H Zheng; P Palese; STEVEN ROSENBERG; A García-Sastre
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.
Virology 1998;249(1):89-97.
1998: Harvey I Pass; S L Schwarz; John R Wunderlich; STEVEN ROSENBERG
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
The cancer journal from Scientific American 1998;4(5):316-23.
1998: Michael I Nishimura; Mary Custer; Susan L Schwarz; Linda L Parker; Arnold Mixon; Timothy M Clay; J R Yannelli; STEVEN ROSENBERG
T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):352-62.
1998: STEVEN ROSENBERG; J C Yang; Donald E White; S M Steinberg
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Annals of surgery 1998;228(3):307-19.
1998: Rongfu Wang; X Wang; S L Johnston; Gang Zeng; Paul F Robbins; STEVEN ROSENBERG
Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens.
Cancer research 1998;58(16):3519-25.
1998: Udai S Kammula; Donald E White; STEVEN ROSENBERG
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Cancer 1998;83(4):797-805.
1998: Willem W Overwijk; A Tsung; Kari R Irvine; Maria R Parkhurst; Theresa J Goletz; K Tsung; MW Carroll; C Liu; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
The Journal of experimental medicine 1998;188(2):277-86.
1998: Y Kawakami; Paul F Robbins; Rongfu Wang; Maria R Parkhurst; Xiaoqiang Kang; STEVEN ROSENBERG
The use of melanosomal proteins in the immunotherapy of melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(4):237-46.
1998: Deborah R Surman; Kari R Irvine; EP Shulman; T M Allweis; STEVEN ROSENBERG; Nicholas P Restifo
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Journal of immunological methods 1998;214(1-2):51-62.
1998: STEVEN ROSENBERG
New opportunities for the development of cancer immunotherapies.
The cancer journal from Scientific American 1998;4 Suppl 1():S1-4.
1998: H Richard Alexander; David L Bartlett; Steven Libutti; Douglas L Fraker; T Moser; STEVEN ROSENBERG
Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1479-89.
1998: David Lee; Donald E White; R Hurst; STEVEN ROSENBERG; James C Yang
Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
The cancer journal from Scientific American 1998;4(2):86-93.
1998: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Mark E Dudley; Susan L Schwarz; Paul J Spiess; John R Wunderlich; Maria R Parkhurst; Y Kawakami; Claudia A Seipp; JH Einhorn; Donald E White
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
Nature medicine 1998;4(3):321-7.
1998: McClellan Walther; B Johnson; D Culley; R Shah; J Weber; David Venzon; JC Yang; W Marston Linehan; STEVEN ROSENBERG
Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
The Journal of urology 1998;159(3):718-22.
1998: JN Cormier; Yasmine Hijazi; Andrea Abati; Patricia A Fetsch; Maria Bettinotti; Seth M Steinberg; STEVEN ROSENBERG; Francesco M Marincola
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
International journal of cancer. Journal international du cancer 1998;75(4):517-24.
1998: Michael E Moran; CJ Calvano; STEVEN ROSENBERG
Stationary mechanical-assist technology for single-surgeon laparoscopic bilateral varicocelectomy.
Journal of endourology / Endourological Society 1998;12(1):71-4.
1998: G Wang; R K Chopra; Richard E Royal; James C Yang; STEVEN ROSENBERG; Patrick Hwu
A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen.
Nature medicine 1998;4(2):168-72.
1998: Rongfu Wang; S L Johnston; Scott Southwood; Alexandro Sette; STEVEN ROSENBERG
Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(2):890-7.
1998: CJ Kim; JN Cormier; MM Roden; Linda Gritz; Gail P Mazzara; Patricia A Fetsch; Yasmine Hijazi; K H Lee; STEVEN ROSENBERG; Francesco M Marincola
Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.
Annals of surgical oncology 1998;5(1):64-76.
1998: JN Cormier; Andrea Abati; Patricia A Fetsch; Yasmine Hijazi; STEVEN ROSENBERG; Francesco M Marincola; Suzanne Topalian
Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(1):27-31.
1998: James C Yang; Alfred E Chang; A R Baker; W F Sindelar; D N Danforth; Suzanne Topalian; T DeLaney; E Glatstein; S M Steinberg; M J Merino; STEVEN ROSENBERG
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):197-203.
1997: STEVEN ROSENBERG; R. Michael Blaese; M K Brenner; A B Deisseroth; F D Ledley; M T Lotze; J M Wilson; Gary Nabel; Kenneth Cornetta; J S Economou; S M Freeman; S R Riddell; E Oldfield; B Gansbacher; Cynthia Dunbar; Robert E Walker; F G Schuening; J A Roth; R G Crystal; M J Welsh; KW Culver; H E Heslop; J Simons; R W Wilmott; R C Boucher
Human gene marker/therapy clinical protocols.
Human gene therapy 1997;8(18):2301-38.
1997: James C Yang; STEVEN ROSENBERG
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
The cancer journal from Scientific American 1997;3 Suppl 1():S79-84.
1997: Richard I Fisher; STEVEN ROSENBERG; Mario Sznol; D R Parkinson; G Fyfe
High-dose aldesleukin in renal cell carcinoma: long-term survival update.
The cancer journal from Scientific American 1997;3 Suppl 1():S70-2.
1997: STEVEN ROSENBERG
Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
The cancer journal from Scientific American 1997;3 Suppl 1():S2-6.
1997: Kari R Irvine; RS Chamberlain; EP Shulman; Deborah R Surman; STEVEN ROSENBERG; Nicholas P Restifo
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
Journal of the National Cancer Institute 1997;89(21):1595-601.
1997: McClellan Walther; JC Yang; Harvey I Pass; W Marston Linehan; STEVEN ROSENBERG
Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.
The Journal of urology 1997;158(5):1675-8.
1997: J M Specht; Gang Wang; M T Do; J S Lam; Richard E Royal; ME Reeves; STEVEN ROSENBERG; Patrick Hwu
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
The Journal of experimental medicine 1997;186(8):1213-21.
1997: Brian J Czerniecki; Charles Carter; L Rivoltini; Gary K Koski; H I Kim; David Weng; JG Roros; Y M Hijazi; Shuwen Xu; STEVEN ROSENBERG; Peter A Cohen
Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(8):3823-37.
1997: JN Cormier; R Hurst; James R Vasselli; David Lee; CJ Kim; M McKee; D Venzon; D White; Francesco M Marincola; STEVEN ROSENBERG
A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):292-300.
1997: CJ Kim; T Prevette; JN Cormier; Willem W Overwijk; MM Roden; Nicholas P Restifo; STEVEN ROSENBERG; Francesco M Marincola
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):276-86.
1997: joel shilyansky; James C Yang; Mary Custer; Paul J Spiess; Arnold Mixon; David J Cole; J J Mulé; STEVEN ROSENBERG; Michael I Nishimura
Identification of a T-cell receptor from a therapeutic murine T-cell clone.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):247-55.
1997: Paul F Robbins; Mona El-Gamil; Yong F Li; EB Fitzgerald; Y Kawakami; STEVEN ROSENBERG
The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(1):303-8.
1997: STEVEN ROSENBERG
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Immunology today 1997;18(4):175-82.
1997: Vincenzo Bronte; MW Carroll; Theresa J Goletz; M Wang; Willem W Overwijk; Francesco M Marincola; STEVEN ROSENBERG; Bernard Moss; Nicholas P Restifo
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(7):3183-8.
1997: Y Kawakami; Jane Battles; Takeshi Kobayashi; W Ennis; X Wang; JP Tupesis; Francesco M Marincola; Paul F Robbins; Vincent J Hearing; M A Gonda; STEVEN ROSENBERG
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Journal of immunological methods 1997;202(1):13-25.
1997: Kari R Irvine; RS Chamberlain; EP Shulman; STEVEN ROSENBERG; Nicholas P Restifo
Route of immunization and the therapeutic impact of recombinant anticancer vaccines.
Journal of the National Cancer Institute 1997;89(5):390-2.
1997: MW Carroll; Willem W Overwijk; R S Chamberlain; STEVEN ROSENBERG; Bernard Moss; Nicholas P Restifo
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Vaccine 1997;15(4):387-94.
1997: Matthew Bloom; Donna Perry-Lalley; Paul F Robbins; Yong Li; Mona El-Gamil; STEVEN ROSENBERG; James C Yang
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
The Journal of experimental medicine 1997;185(3):453-9.
1997: Xiaoqiang Kang; Paul F Robbins; EB Fitzgerald; Rongfu Wang; STEVEN ROSENBERG; Y Kawakami
Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Cancer research 1997;57(2):202-5.
1997: Y Kawakami; STEVEN ROSENBERG
Human tumor antigens recognized by T-cells.
Immunologic research 1997;16(4):313-39.
1997: David H Adams; J R Yannelli; W Newman; T Lawley; E Ades; STEVEN ROSENBERG; S Shaw
Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis.
British journal of cancer 1997;75(10):1421-31.
1997: Y Kawakami; STEVEN ROSENBERG
Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
International reviews of immunology 1997;14(2-3):173-92.
1997: Y Zhai; James C Yang; Paul J Spiess; Michael I Nishimura; Willem W Overwijk; B Roberts; Nicholas P Restifo; STEVEN ROSENBERG
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):15-25.
1997: J N Cormier; M L Salgaller; T Prevette; KC Barracchini; L Rivoltini; Nicholas P Restifo; STEVEN ROSENBERG; Francesco M Marincola
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
The cancer journal from Scientific American 1997;3(1):37-44.
1996: M E Reeves; Richard E Royal; J S Lam; STEVEN ROSENBERG; Patrick Hwu
Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.
Cancer research 1996;56(24):5672-7.
1996: M Alexander; Michael L Salgaller; E Celis; A Sette; W A Barnes; STEVEN ROSENBERG; MA Steller
Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
American journal of obstetrics and gynecology 1996;175(6):1586-93.
1996: Rongfu Wang; Ettore Appella; Y Kawakami; Xiaoqiang Kang; STEVEN ROSENBERG
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.
The Journal of experimental medicine 1996;184(6):2207-16.
1996: STEVEN ROSENBERG; R. Michael Blaese; M K Brenner; A B Deisseroth; F D Ledley; M T Lotze; J M Wilson; Gary Nabel; Kenneth Cornetta; J S Economou; SM Freeman; S R Riddell; E Oldfield; B Gansbacher; Cynthia Dunbar; Robert E Walker; F G Schuening; J A Roth; Helen-Ann Brown Epstein; M J Welsh; KW Culver; H E Heslop; J Simons; R W Wilmott; P Tiberghien
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(18):2287-313.
1996: STEVEN ROSENBERG
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
Journal of the National Cancer Institute 1996;88(22):1635-44.
1996: Michael L Salgaller; Francesco M Marincola; JN Cormier; STEVEN ROSENBERG
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
Cancer research 1996;56(20):4749-57.
1996: STEVEN ROSENBERG
Secrecy in research: cooperation and costimulation in immunology.
Current opinion in immunology 1996;8(5):611-2.
1996: Maria R Parkhurst; Michael L Salgaller; S Southwood; Paul F Robbins; A Sette; STEVEN ROSENBERG; Y Kawakami
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(6):2539-48.
1996: R D Dadmarz; A Ordoubadi; Arnold Mixon; C O Thompson; K C Barracchini; Yasmine Hijazi; MA Steller; STEVEN ROSENBERG; Douglas J Schwartzentruber
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
The cancer journal from Scientific American 1996;2(5):263-72.
1996: Rongfu Wang; STEVEN ROSENBERG
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Journal of leukocyte biology 1996;60(3):296-309.
1996: STEVEN ROSENBERG; R. Michael Blaese; M K Brenner; A B Deisseroth; F D Ledley; M T Lotze; J M Wilson; Gary Nabel; Kenneth Cornetta; J S Economou; SM Freeman; S R Riddell; E Oldfield; B Gansbacher; Cynthia Dunbar; Robert E Walker; F G Schuening; J A Roth; Helen-Ann Brown Epstein; M J Welsh; KW Culver; H E Heslop; J Simons; R W Wilmott; P Aebischer
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(13):1621-47.
1996: James J Mulé; Mary Custer; B Averbook; J C Yang; J S Weber; D V Goeddel; STEVEN ROSENBERG; T J Schall
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations.
Human gene therapy 1996;7(13):1545-53.
1996: J S Lam; M E Reeves; R Cowherd; STEVEN ROSENBERG; Patrick Hwu
Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope.
Human gene therapy 1996;7(12):1415-22.
1996: Francesco M Marincola; Licia Rivoltini; Michael L Salgaller; M Player; STEVEN ROSENBERG
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):266-77.
1996: R S Chamberlain; MW Carroll; Vincenzo Bronte; Patrick Hwu; S Warren; J C Yang; Michael I Nishimura; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer research 1996;56(12):2832-6.
1996: Y Kawakami; Paul F Robbins; STEVEN ROSENBERG
Human melanoma antigens recognized by T lymphocytes.
The Keio journal of medicine 1996;45(2):100-8.
1996: Harvey I Pass; D J Mew; K C Kranda; BK Temeck; J S Donington; STEVEN ROSENBERG
Isolated lung perfusion with tumor necrosis factor for pulmonary metastases.
The Annals of thoracic surgery 1996;61(6):1609-17.
1996: Francesco M Marincola; Yasmine Hijazi; Patricia A Fetsch; Michael L Salgaller; Licia Rivoltini; JN Cormier; TB Simonis; P H Duray; M Herlyn; Y Kawakami; STEVEN ROSENBERG
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):192-205.
1996: Suzanne Topalian; M I Gonzales; Maria R Parkhurst; Y F Li; S Southwood; A Sette; STEVEN ROSENBERG; Paul F Robbins
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
The Journal of experimental medicine 1996;183(5):1965-71.
1996: J B Rao; R S Chamberlain; Vincenzo Bronte; MW Carroll; Kari R Irvine; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(9):3357-65.
1996: Richard E Royal; Seth M Steinberg; R S Krouse; G Heywood; Donald E White; Patrick Hwu; Francesco M Marincola; D R Parkinson; Douglas J Schwartzentruber; Suzanne Topalian; J C Yang; STEVEN ROSENBERG
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
The cancer journal from Scientific American 1996;2(2):91-8.
1996: Paul F Robbins; Mona El-Gamil; Y F Li; Y Kawakami; DJ Loftus; Ettore Appella; STEVEN ROSENBERG
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
The Journal of experimental medicine 1996;183(3):1185-92.
1996: Rongfu Wang; Maria R Parkhurst; Y Kawakami; Paul F Robbins; STEVEN ROSENBERG
Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
The Journal of experimental medicine 1996;183(3):1131-40.
1996: J R Yannelli; C Hyatt; S McConnell; Kenneth Hines; L Jacknin; L Parker; M Sanders; STEVEN ROSENBERG
Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
International journal of cancer. Journal international du cancer 1996;65(4):413-21.
1996: STEVEN ROSENBERG
Secrecy in medical research.
The New England journal of medicine 1996;334(6):392-4.
1996: Douglas L Fraker; H Richard Alexander; M Andrich; STEVEN ROSENBERG
Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):479-89.
1996: Nicholas P Restifo; Francesco M Marincola; Y Kawakami; Jeffery Taubenberger; J R Yannelli; STEVEN ROSENBERG
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Journal of the National Cancer Institute 1996;88(2):100-8.
1996: Y Zhai; J C Yang; Y Kawakami; Paul J Spiess; Samuel C Wadsworth; L M Cardoza; L A Couture; AE Smith; STEVEN ROSENBERG
Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(2):700-10.
1996: Y Kawakami; STEVEN ROSENBERG
T-cell recognition of self peptides as tumor rejection antigens.
Immunologic research 1996;15(3):179-90.
1996: STEVEN ROSENBERG; Y Kawakami; Paul F Robbins; Rongfu Wang
Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.
Advances in cancer research 1996;70():145-77.
1996: STEVEN ROSENBERG; Donald E White
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):81-4.
1996: C J Kim; Jeffery Taubenberger; TB Simonis; Donald E White; STEVEN ROSENBERG; Francesco M Marincola
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):50-8.
1996: Y Kawakami; Paul F Robbins; Rongfu Wang; STEVEN ROSENBERG
Identification of tumor-regression antigens in melanoma.
Important advances in oncology 1996;():3-21.
1996: C J Bartels; STEVEN ROSENBERG; J C Yang
Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells.
Annals of surgical oncology 1996;3(1):67-73.
1996: McClellan Walther; S B Jennings; P L Choyke; M Andrich; Kathleen Hurley; W Marston Linehan; STEVEN ROSENBERG; Richard B Alexander
Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.
World journal of urology 1996;14 Suppl 1():S2-7.
1996: Bernard Moss; MW Carroll; Linda S Wyatt; Jack R Bennink; Vanessa M Hirsch; S Goldstein; W R Elkins; Thomas R Fuerst; Jeffrey D Lifson; M Piatak; Nicholas P Restifo; Willem W Overwijk; R Chamberlain; STEVEN ROSENBERG; G Sutter
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.
Advances in experimental medicine and biology 1996;397():7-13.
1996: STEVEN ROSENBERG
The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Annual review of medicine 1996;47():481-91.
1996: Kari R Irvine; J B Rao; STEVEN ROSENBERG; Nicholas P Restifo
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):238-45.
1996: P W Chen; M Wang; Vincenzo Bronte; Y Zhai; STEVEN ROSENBERG; Nicholas P Restifo
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):224-31.
1995: R S Krouse; Richard E Royal; G Heywood; Bruce D Weintraub; Donald E White; Seth M Steinberg; STEVEN ROSENBERG; Douglas J Schwartzentruber
Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):272-8.
1995: Michael L Salgaller; A Afshar; Francesco M Marincola; Licia Rivoltini; Y Kawakami; STEVEN ROSENBERG
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Cancer research 1995;55(21):4972-9.
1995: R. Michael Blaese; KW Culver; A D Miller; Charles S Carter; Thomas A Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; STEVEN ROSENBERG; HARVEY KLEIN; M Berger; Craig A Mullen; W J Ramsey; L Muul; Richard A Morgan; W French Anderson
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Science (New York, N.Y.) 1995;270(5235):475-80.
1995: M Wang; P W Chen; Vincenzo Bronte; STEVEN ROSENBERG; Nicholas P Restifo
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):139-46.
1995: S Minamoto; J Treisman; William David Hankins; K Sugamura; STEVEN ROSENBERG
Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors.
Blood 1995;86(6):2281-7.
1995: J C Yang; Suzanne Topalian; Douglas J Schwartzentruber; D R Parkinson; Francesco M Marincola; J S Weber; Claudia A Seipp; Donald E White; STEVEN ROSENBERG
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Cancer 1995;76(4):687-94.
1995: N R Markus; STEVEN ROSENBERG; Suzanne Topalian
Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(8):739-46.
1995: Patrick Hwu; J C Yang; R Cowherd; J Treisman; G E Shafer; Z Eshhar; STEVEN ROSENBERG
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Cancer research 1995;55(15):3369-73.
1995: Xiaoqiang Kang; Y Kawakami; Mona El-Gamil; Rongfu Wang; Kazuyasu Sakaguchi; J R Yannelli; Ettore Appella; STEVEN ROSENBERG; Paul F Robbins
Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(3):1343-8.
1995: Licia Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; Arnold Mixon; Nicholas P Restifo; Suzanne Topalian; TB Simonis; STEVEN ROSENBERG
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Cancer research 1995;55(14):3149-57.
1995: Douglas L Fraker; H Richard Alexander; M Andrich; STEVEN ROSENBERG
Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
The cancer journal from Scientific American 1995;1(2):122-30.
1995: STEVEN ROSENBERG
The development of new cancer therapies based on the molecular identification of cancer regression antigens.
The cancer journal from Scientific American 1995;1(2):90-100.
1995: G R Heywood; STEVEN ROSENBERG; J S Weber
Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2.
Journal of the National Cancer Institute 1995;87(12):915-22.
1995: Paul F Robbins; Mona El-Gamil; Y F Li; Suzanne Topalian; Licia Rivoltini; Kazuyasu Sakaguchi; Ettore Appella; Y Kawakami; STEVEN ROSENBERG
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(11):5944-50.
1995: Vincenzo Bronte; K Tsung; J B Rao; P W Chen; M Wang; STEVEN ROSENBERG; Nicholas P Restifo
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(10):5282-92.
1995: Francesco M Marincola; Donald E White; A P Wise; STEVEN ROSENBERG
Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1110-22.
1995: M Wang; Vincenzo Bronte; P W Chen; Linda Gritz; D Panicali; STEVEN ROSENBERG; Nicholas P Restifo
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4685-92.
1995: Kari R Irvine; B J McCabe; STEVEN ROSENBERG; Nicholas P Restifo
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4651-7.
1995: Nicholas P Restifo; I Bacík; Kari R Irvine; jon yewdell; B J McCabe; R W Anderson; L C Eisenlohr; STEVEN ROSENBERG; Jack R Bennink
Antigen processing in vivo and the elicitation of primary CTL responses.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4414-22.
1995: M K Jakobsen; Nicholas P Restifo; Peter A Cohen; Francesco M Marincola; L B Cheshire; W Marston Linehan; STEVEN ROSENBERG; Richard B Alexander
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(4):222-8.
1995: B D Cheson; STEVEN ROSENBERG; P H Phillips
Clinical trials referral resource. Clinical trials at the surgery branch of the NCI.
Oncology (Williston Park, N.Y.) 1995;9(5):453-4.
1995: Y Kawakami; S Eliyahu; C Jennings; Kazuyasu Sakaguchi; Xiaoqiang Kang; S Southwood; Paul F Robbins; A Sette; Ettore Appella; STEVEN ROSENBERG
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(8):3961-8.
1995: B J McCabe; Kari R Irvine; Michael I Nishimura; J C Yang; Paul J Spiess; EP Shulman; STEVEN ROSENBERG; Nicholas P Restifo
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
Cancer research 1995;55(8):1741-7.
1995: M P MacFarlane; J C Yang; A S Guleria; R L White; Claudia A Seipp; JH Einhorn; Donald E White; STEVEN ROSENBERG
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
Cancer 1995;75(4):1030-7.
1995: David J Cole; D P Weil; joel shilyansky; Mary Custer; Y Kawakami; STEVEN ROSENBERG; Michael I Nishimura
Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.
Cancer research 1995;55(4):748-52.
1995: Rongfu Wang; Paul F Robbins; Y Kawakami; Xiaoqiang Kang; STEVEN ROSENBERG
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.
The Journal of experimental medicine 1995;181(2):799-804.
1995: M K Sgagias; D C Gagneton; STEVEN ROSENBERG; David N Danforth
Cellular characterization and retroviral transduction of short-term breast cancer cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(2):88-97.
1995: E J Stevens; L Jacknin; Paul F Robbins; Y Kawakami; Mona El-Gamil; STEVEN ROSENBERG; J R Yannelli
Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(2):762-71.
1995: J C Yang; Douglas L Fraker; A K Thom; Harvey I Pass; STEVEN ROSENBERG
Isolation perfusion with tumor necrosis factor-alpha, interferon-gamma, and hyperthermia in the treatment of localized and metastatic cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1995;138():161-6.
1995: S E Ettinghausen; STEVEN ROSENBERG
Immunotherapy and gene therapy of cancer.
Advances in surgery 1995;28():223-54.
1995: R Dadmarz; M K Sgagias; STEVEN ROSENBERG; Douglas J Schwartzentruber
CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.
Cancer immunology, immunotherapy : CII 1995;40(1):1-9.
1995: J Treisman; Patrick Hwu; S Minamoto; G E Shafer; R Cowherd; Richard A Morgan; STEVEN ROSENBERG
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen.
Blood 1995;85(1):139-45.
1995: A K Thom; H Richard Alexander; M P Andrich; W C Barker; STEVEN ROSENBERG; Douglas L Fraker
Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):264-73.
1995: Richard B Alexander; E B Fitzgerald; Arnold Mixon; C S Carter; M Jakobsen; Peter A Cohen; STEVEN ROSENBERG
Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(1):39-46.
1994: R L White; Douglas J Schwartzentruber; A Guleria; M P MacFarlane; Donald E White; E Tucker; STEVEN ROSENBERG
Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
Cancer 1994;74(12):3212-22.
1994: David J Cole; D P Weil; Peter Shamamian; Licia Rivoltini; Y Kawakami; Suzanne Topalian; C Jennings; S Eliyahu; STEVEN ROSENBERG; Michael I Nishimura
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cancer research 1994;54(20):5265-8.
1994: Suzanne Topalian; Licia Rivoltini; M Mancini; N R Markus; Paul F Robbins; Y Kawakami; STEVEN ROSENBERG
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(20):9461-5.
1994: STEVEN ROSENBERG
Classification of lymphoid neoplasms.
Blood 1994;84(5):1359-60.
1994: STEVEN ROSENBERG
The gene therapy of cancer.
Preventive medicine 1994;23(5):624-6.
1994: STEVEN ROSENBERG; J R Yannelli; J C Yang; Suzanne Topalian; Douglas J Schwartzentruber; J S Weber; D R Parkinson; Claudia A Seipp; JH Einhorn; Donald E White
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Journal of the National Cancer Institute 1994;86(15):1159-66.
1994: Michael I Nishimura; Y Kawakami; P Charmley; B O'Neil; joel shilyansky; J R Yannelli; STEVEN ROSENBERG; Leroy Hood
T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(2):85-94.
1994: Peter Shamamian; M Mancini; Y Kawakami; Nicholas P Restifo; STEVEN ROSENBERG; Suzanne Topalian
Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Cancer immunology, immunotherapy : CII 1994;39(2):73-83.
1994: Michael L Salgaller; J S Weber; Scott Koenig; J R Yannelli; STEVEN ROSENBERG
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Cancer immunology, immunotherapy : CII 1994;39(2):105-16.
1994: B R Minev; B J McFarland; Paul J Spiess; STEVEN ROSENBERG; Nicholas P Restifo
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
Cancer research 1994;54(15):4155-61.
1994: Y Kawakami; S Eliyahu; C H Delgado; Paul F Robbins; Kazuyasu Sakaguchi; Ettore Appella; J R Yannelli; G J Adema; Toru Miki; STEVEN ROSENBERG
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(14):6458-62.
1994: H Kim; STEVEN ROSENBERG; Seth M Steinberg; David J Cole; J S Weber
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):60-5.
1994: J Treisman; Patrick Hwu; J R Yannelli; G E Shafer; R Cowherd; D Samid; STEVEN ROSENBERG
Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid.
Cellular immunology 1994;156(2):448-57.
1994: Douglas J Schwartzentruber; S S Hom; R Dadmarz; Donald E White; J R Yannelli; Seth M Steinberg; STEVEN ROSENBERG; Suzanne Topalian
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1475-83.
1994: Suzanne Topalian; Licia Rivoltini; M Mancini; J Ng; R J Hartzman; STEVEN ROSENBERG
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
International journal of cancer. Journal international du cancer 1994;58(1):69-79.
1994: Y Kawakami; S Eliyahu; Kazuyasu Sakaguchi; Paul F Robbins; Licia Rivoltini; J R Yannelli; Ettore Appella; STEVEN ROSENBERG
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
The Journal of experimental medicine 1994;180(1):347-52.
1994: Paul F Robbins; Mona El-Gamil; Y Kawakami; E Stevens; J R Yannelli; STEVEN ROSENBERG
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.
Cancer research 1994;54(12):3124-6.
1994: H W Pogrebniak; C J Witt; R Terrill; K Kranda; William D Travis; STEVEN ROSENBERG; Harvey I Pass
Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials.
The Annals of thoracic surgery 1994;57(6):1477-83.
1994: Patrick Hwu; STEVEN ROSENBERG
The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy.
Annals of the New York Academy of Sciences 1994;716():188-97; discussion 197-203.
1994: David J Cole; Jeffery Taubenberger; B A Pockaj; J R Yannelli; Charles Carter; Jorge Carrasquillo; S Leitman; Seth M Steinberg; STEVEN ROSENBERG; Y C Yang
Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.
Cancer immunology, immunotherapy : CII 1994;38(5):299-303.
1994: J Weber; H Gunn; J Yang; D Parkinson; Suzanne Topalian; Douglas J Schwartzentruber; S Ettinghausen; D Levitt; STEVEN ROSENBERG
A phase I trial of intravenous interleukin-6 in patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(4):292-302.
1994: Y Kawakami; S Eliyahu; C H Delgado; Paul F Robbins; Licia Rivoltini; Suzanne Topalian; Toru Miki; STEVEN ROSENBERG
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(9):3515-9.
1994: Francesco M Marincola; S Ettinghausen; Peter A Cohen; L B Cheshire; Nicholas P Restifo; James J Mulé; STEVEN ROSENBERG
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(7):3500-13.
1994: J Weber; Michael L Salgaller; D Samid; B Johnson; M Herlyn; N Lassam; J Treisman; STEVEN ROSENBERG
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Cancer research 1994;54(7):1766-71.
1994: joel shilyansky; Michael I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; STEVEN ROSENBERG
T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2829-33.
1994: STEVEN ROSENBERG; J C Yang; Suzanne Topalian; Douglas J Schwartzentruber; J S Weber; D R Parkinson; Claudia A Seipp; JH Einhorn; Donald E White
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
JAMA : the journal of the American Medical Association 1994;271(12):907-13.
1994: B A Pockaj; R M Sherry; JP Wei; J R Yannelli; C S Carter; S F Leitman; J A Carasquillo; Seth M Steinberg; STEVEN ROSENBERG; J C Yang
Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Cancer 1994;73(6):1731-7.
1994: STEVEN ROSENBERG
Advancing your practice with dental lasers.
Dental economics - oral hygiene 1994;84(3):84-5.
1994: A B Bakker; Marco W Schreurs; Annemiek J de Boer; Y Kawakami; STEVEN ROSENBERG; Gosse J Adema; Carl G Figdor
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
The Journal of experimental medicine 1994;179(3):1005-9.
1994: Peter A Cohen; P J Cohen; STEVEN ROSENBERG; James J Mulé
CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens.
Cancer research 1994;54(4):1055-8.
1994: S G Marcus; Donna Perry-Lalley; James J Mulé; STEVEN ROSENBERG; J C Yang
The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):105-12.
1994: P J Cohen; Peter A Cohen; STEVEN ROSENBERG; Stephen I Katz; J J Mulé
Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.
European journal of immunology 1994;24(2):315-9.
1994: STEVEN ROSENBERG; C M Eytalis
Health reform and employee health benefits programs.
Employee relations law journal 1994;19(4):471-83.
1994: Patrick Hwu; STEVEN ROSENBERG
The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
Cancer detection and prevention 1994;18(1):43-50.
1994: B A Pockaj; J C Yang; M T Lotze; Julie R Lange; W F Spencer; Seth M Steinberg; Suzanne Topalian; Douglas J Schwartzentruber; Donald E White; STEVEN ROSENBERG
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(1):22-8.
1994: M G Wang; R Zakut; H Yi; STEVEN ROSENBERG; O W McBride
Localization of the MAGE1 gene encoding a human melanoma antigen to chromosome Xq28.
Cytogenetics and cell genetics 1994;67(2):116-9.
1994: Peter A Cohen; Daniel H Fowler; H Kim; R L White; Brian J Czerniecki; Charles Carter; Ronald E Gress; STEVEN ROSENBERG
Propagation of mouse and human T cells with defined antigen specificity and function.
Ciba Foundation symposium 1994;187():179-93; discussion 194-7.
1993: S G Marcus; Maria J Merino; E Glatstein; T F DeLaney; S M Steinberg; STEVEN ROSENBERG; J C Yang
Long-term outcome in 87 patients with low-grade soft-tissue sarcoma.
Archives of surgery (Chicago, Ill. : 1960) 1993;128(12):1336-43.
1993: Eitan Shiloni; S E Karp; Mary Custer; joel shilyansky; Nicholas P Restifo; STEVEN ROSENBERG; James J Mulé
Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Cancer immunology, immunotherapy : CII 1993;37(5):286-92.
1993: Nicholas P Restifo; Y Kawakami; Francesco M Marincola; Peter Shamamian; A Taggarse; F Esquivel; STEVEN ROSENBERG
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):182-90.
1993: STEVEN ROSENBERG; W French Anderson; M Blaese; Patrick Hwu; J R Yannelli; J C Yang; Suzanne Topalian; Douglas J Schwartzentruber; J S Weber; S E Ettinghausen
The development of gene therapy for the treatment of cancer.
Annals of surgery 1993;218(4):455-63; discussion 463-4.
1993: Peter A Cohen; H Kim; Daniel H Fowler; Ronald E Gress; M K Jakobsen; Richard B Alexander; James J Mulé; Charles Carter; STEVEN ROSENBERG
Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):242-52.
1993: McClellan Walther; Richard B Alexander; Gary Weiss; David Venzon; A Berman; Harvey I Pass; W Marston Linehan; STEVEN ROSENBERG
Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.
Urology 1993;42(3):250-7; discussion 257-8.
1993: Douglas J Schwartzentruber; Maryalice Stetler-Stevenson; STEVEN ROSENBERG; Suzanne Topalian
Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.
Blood 1993;82(4):1204-11.
1993: Bert O Neil; Y Kawakami; Nicholas P Restifo; Jack R Bennink; jon yewdell; STEVEN ROSENBERG
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(3):1410-8.
1993: S G Marcus; P L Choyke; Robert E Reiter; G S Jaffe; Richard B Alexander; W Marston Linehan; STEVEN ROSENBERG; McClellan Walther
Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.
The Journal of urology 1993;150(2 Pt 1):463-6.
1993: Y Kawakami; Michael I Nishimura; Nicholas P Restifo; Suzanne Topalian; Bert O Neil; joel shilyansky; J R Yannelli; STEVEN ROSENBERG
T-cell recognition of human melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):88-93.
1993: M Ogasawara; STEVEN ROSENBERG
Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Cancer research 1993;53(15):3561-8.
1993: J P Long; McClellan Walther; Richard B Alexander; W Marston Linehan; STEVEN ROSENBERG
The management of isolated renal recurrence of renal cell carcinoma following complete response to interleukin-2 based immunotherapy.
The Journal of urology 1993;150(1):176-8.
1993: Patrick Hwu; G E Shafer; J Treisman; D G Schindler; G Gross; R Cowherd; STEVEN ROSENBERG; Z Eshhar
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.
The Journal of experimental medicine 1993;178(1):361-6.
1993: J R Yannelli; C Hyatt; S Johnson; Patrick Hwu; STEVEN ROSENBERG
Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2).
Journal of immunological methods 1993;161(1):77-90.
1993: Francesco M Marincola; J Balkissoon; Douglas J Schwartzentruber; S S Hom; R Concepcion; S G Marcus; J Yannelli; Suzanne Topalian; D R Parkinson; STEVEN ROSENBERG
Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(4):282-8.
1993: STEVEN ROSENBERG; M T Lotze; J C Yang; Suzanne Topalian; Alfred E Chang; Douglas J Schwartzentruber; P Aebersold; Susan F Leitman; W Marston Linehan; Claudia A Seipp
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Journal of the National Cancer Institute 1993;85(8):622-32.
1993: W F Sindelar; T J Kinsella; P W Chen; T F DeLaney; Joel E Tepper; STEVEN ROSENBERG; E Glatstein
Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial.
Archives of surgery (Chicago, Ill. : 1960) 1993;128(4):402-10.
1993: W Marston Linehan; McClellan Walther; Richard B Alexander; STEVEN ROSENBERG
Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
Seminars in urology 1993;11(1):41-3.
1993: B J Averbook; J P Wei; Donna Perry-Lalley; STEVEN ROSENBERG; J C Yang
A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes.
Lymphokine and cytokine research 1993;12(1):1-8.
1993: Nicholas P Restifo; F Esquivel; Y Kawakami; jon yewdell; James J Mulé; STEVEN ROSENBERG; Jack R Bennink
Identification of human cancers deficient in antigen processing.
The Journal of experimental medicine 1993;177(2):265-72.
1993: S E Karp; A Farber; J C Salo; Patrick Hwu; G Jaffe; A L Asher; Eitan Shiloni; Nicholas P Restifo; James J Mulé; STEVEN ROSENBERG
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(3):896-908.
1993: S S Hom; Douglas J Schwartzentruber; STEVEN ROSENBERG; Suzanne Topalian
Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):18-30.
1993: S S Hom; STEVEN ROSENBERG; Suzanne Topalian
Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.
Cancer immunology, immunotherapy : CII 1993;36(1):1-8.
1993: W F Sindelar; T J Kinsella; Joel E Tepper; T F DeLaney; M M Maher; R Smith; STEVEN ROSENBERG; E Glatstein
Randomized trial of intraoperative radiotherapy in carcinoma of the stomach.
American journal of surgery 1993;165(1):178-86; discussion 186-7.
1993: B A Pockaj; Suzanne Topalian; Seth M Steinberg; Donald E White; STEVEN ROSENBERG
Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):136-47.
1993: R Zakut; Suzanne Topalian; Y Kawakami; M Mancini; S Eliyahu; STEVEN ROSENBERG
Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
Cancer research 1993;53(1):5-8.
1993: J C Yang; E Shlasko; J L Ritchey; J G Landry; D E White; STEVEN ROSENBERG
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):355-9.
1992: Francesco M Marincola; David Venzon; D White; Joshua Rubin; M T Lotze; TB Simonis; J Balkissoon; STEVEN ROSENBERG; D R Parkinson
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Cancer research 1992;52(23):6561-6.
1992: STEVEN ROSENBERG
Gene therapy for cancer.
JAMA : the journal of the American Medical Association 1992;268(17):2416-9.
1992: Julie R Lange; A A Raubitschek; B A Pockaj; W F Spencer; M T Lotze; Suzanne Topalian; J C Yang; STEVEN ROSENBERG
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):265-71.
1992: Suzanne Topalian; S S Hom; Y Kawakami; M Mancini; Douglas J Schwartzentruber; R Zakut; STEVEN ROSENBERG
Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):203-6.
1992: James J Mulé; D L Jicha; STEVEN ROSENBERG
The use of congenitally immunodeficient mice to study human tumor metastases and immunotherapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):196-8.
1992: S E Karp; Patrick Hwu; A Farber; Nicholas P Restifo; M Kriegler; James J Mulé; STEVEN ROSENBERG
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(6):2076-81.
1992: James J Mulé; S G Marcus; J C Yang; J S Weber; STEVEN ROSENBERG
Clinical application of IL6 in cancer therapy.
Research in immunology 1992;143(7):777-9.
1992: Martin G Sanda; E Bolton; James J Mulé; STEVEN ROSENBERG
In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(2):132-7.
1992: Patrick Hwu; S Schwarz; Mary Custer; C A Smith; James J Mulé; STEVEN ROSENBERG
Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes.
Journal of immunological methods 1992;151(1-2):139-47.
1992: Douglas J Schwartzentruber; D Solomon; STEVEN ROSENBERG; Suzanne Topalian
Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(1):1-12.
1992: H W Pogrebniak; Gabriel P Haas; W M Linehan; STEVEN ROSENBERG; Harvey I Pass
Renal cell carcinoma: resection of solitary and multiple metastases.
The Annals of thoracic surgery 1992;54(1):33-8.
1992: Nicholas P Restifo; Paul J Spiess; S E Karp; James J Mulé; STEVEN ROSENBERG
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
The Journal of experimental medicine 1992;175(6):1423-31.
1992: D L Jicha; S Schwarz; James J Mulé; STEVEN ROSENBERG
Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Cellular immunology 1992;141(1):71-83.
1992: James J Mulé; Mary Custer; William D Travis; STEVEN ROSENBERG
Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(8):2622-9.
1992: Richard B Alexander; E S Bolton; Scott Koenig; G M Jones; Suzanne Topalian; Carl H June; STEVEN ROSENBERG
Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry.
Journal of immunological methods 1992;148(1-2):131-41.
1992: R M Sherry; Harvey I Pass; STEVEN ROSENBERG; J C Yang
Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Cancer 1992;69(7):1850-5.
1992: P L Choyke; D L Miller; M T Lotze; J M Whiteis; B Ebbitt; STEVEN ROSENBERG
Delayed reactions to contrast media after interleukin-2 immunotherapy.
Radiology 1992;183(1):111-4.
1992: STEVEN ROSENBERG
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):180-99.
1992: Y Kawakami; R Zakut; Suzanne Topalian; H Stötter; STEVEN ROSENBERG
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(2):638-43.
1992: D L Jicha; J R Yannelli; Mary Custer; J Colandrea; J Taubenberger; James J Mulé; STEVEN ROSENBERG
The persistence of human peripheral lymphocytes, tumor infiltrating lymphocytes, and colon adenocarcinomas in immunodeficient mice.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(1):19-29.
1992: J S Weber; J C Yang; Suzanne Topalian; Douglas J Schwartzentruber; Donald E White; STEVEN ROSENBERG
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(1):33-40.
1992: STEVEN ROSENBERG
Gene therapy of cancer.
Important advances in oncology 1992;():17-38.
1991: Douglas J Schwartzentruber; Donald E White; M H Zweig; Bruce D Weintraub; STEVEN ROSENBERG
Thyroid dysfunction associated with immunotherapy for patients with cancer.
Cancer 1991;68(11):2384-90.
1991: J C Yang; Susan L Schwarz; Donna Perry-Lalley; STEVEN ROSENBERG
Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Lymphokine and cytokine research 1991;10(6):475-80.
1991: B A Pockaj; STEVEN ROSENBERG
Lack of antihypertensive effect of interleukin-2 administration in humans.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(6):456-9.
1991: Richard B Alexander; STEVEN ROSENBERG
Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(6):389-97.
1991: D L Jicha; James J Mulé; STEVEN ROSENBERG
Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.
The Journal of experimental medicine 1991;174(6):1511-5.
1991: S F Stinson; T F DeLaney; J Greenberg; J C Yang; M H Lampert; J E Hicks; David Venzon; Donald E White; STEVEN ROSENBERG; E J Glatstein
Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma.
International journal of radiation oncology, biology, physics 1991;21(6):1493-9.
1991: R M Sherry; STEVEN ROSENBERG; J C Yang
Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):371-5.
1991: STEVEN ROSENBERG
Immunotherapy and gene therapy of cancer.
Cancer research 1991;51(18 Suppl):5074s-5079s.
1991: Nicholas P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; Jack R Bennink; James J Mulé; jon yewdell; STEVEN ROSENBERG
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(4):1453-9.
1991: H W Pogrebniak; J A Roth; Seth M Steinberg; STEVEN ROSENBERG; Harvey I Pass
Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma.
The Annals of thoracic surgery 1991;52(2):197-203.
1991: R J Barth; James J Mulé; A L Asher; Martin G Sanda; STEVEN ROSENBERG
Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor.
Journal of immunological methods 1991;140(2):269-79.
1991: P Aebersold; C Hyatt; S Johnson; Kenneth Hines; L Korcak; M Sanders; M Lotze; Suzanne Topalian; J Yang; STEVEN ROSENBERG
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
Journal of the National Cancer Institute 1991;83(13):932-7.
1991: STEVEN ROSENBERG
Hospitals grapple with HCFA's rules for clinical labs.
Trustee : the journal for hospital governing boards 1991;44(6):18-9.
1991: S S Hom; Suzanne Topalian; TB Simonis; M Mancini; STEVEN ROSENBERG
Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):153-64.
1991: S N Bock; R B Cameron; P Kragel; James J Mulé; STEVEN ROSENBERG
Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
Cancer research 1991;51(10):2649-54.
1991: Douglas J Schwartzentruber; Suzanne Topalian; M Mancini; STEVEN ROSENBERG
Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(10):3674-81.
1991: A L Asher; James J Mulé; A Kasid; Nicholas P Restifo; J C Salo; C M Reichert; G Jaffe; B Fendly; M Kriegler; STEVEN ROSENBERG
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(9):3227-34.
1991: KW Culver; Kenneth Cornetta; R Morgan; S Morecki; P Aebersold; A Kasid; M Lotze; STEVEN ROSENBERG; W French Anderson; R. Michael Blaese
Lymphocytes as cellular vehicles for gene therapy in mouse and man.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3155-9.
1991: R A Wong; Richard B Alexander; Raj K Puri; STEVEN ROSENBERG
In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(2):120-30.
1991: R M Karpati; S M Banks; B Malissen; STEVEN ROSENBERG; M A Sheard; J S Weber; Richard J Hodes
Phenotypic characterization of murine tumor-infiltrating T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(6):2043-51.
1991: James J Mulé; D L Jicha; P M Aebersold; William D Travis; STEVEN ROSENBERG
Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice.
Journal of the National Cancer Institute 1991;83(5):350-5.
1991: R J Barth; James J Mulé; Paul J Spiess; STEVEN ROSENBERG
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.
The Journal of experimental medicine 1991;173(3):647-58.
1991: S Morecki; E Karson; Kenneth Cornetta; A Kasid; P Aebersold; R. Michael Blaese; W French Anderson; STEVEN ROSENBERG
Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII 1991;32(6):342-52.
1991: A T Lefor; STEVEN ROSENBERG
The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
The Journal of surgical research 1991;50(1):15-23.
1991: R E Feinfield; R J Hesse; STEVEN ROSENBERG
Orbital inflammatory disease associated with systemic lupus erythematosus.
Southern medical journal 1991;84(1):98-9.
1990: A H Kragel; William D Travis; R G Steis; STEVEN ROSENBERG; W C Roberts
Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.
Cancer 1990;66(7):1513-6.
1990: Fox Bernard; Paul J Spiess; A Kasid; R Puri; James J Mulé; J S Weber; STEVEN ROSENBERG
In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Journal of biological response modifiers 1990;9(5):499-511.
1990: S Morecki; Suzanne Topalian; W W Myers; D Okrongly; T B Okarma; STEVEN ROSENBERG
Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks.
Journal of biological response modifiers 1990;9(5):463-74.
1990: Raj K Puri; William D Travis; STEVEN ROSENBERG
In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
Cancer research 1990;50(17):5543-50.
1990: C N Robertson; W Marston Linehan; Harvey I Pass; L G Gomella; Gabriel P Haas; A Berman; M Merino; STEVEN ROSENBERG
Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
The Journal of urology 1990;144(3):614-7; discussion 617-8.
1990: Richard B Alexander; STEVEN ROSENBERG
Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(5):1615-20.
1990: STEVEN ROSENBERG; P Aebersold; Kenneth Cornetta; A Kasid; Richard A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; Suzanne Topalian
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
The New England journal of medicine 1990;323(9):570-8.
1990: A Kasid; E P Director; M C Stovroff; M T Lotze; STEVEN ROSENBERG
Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.
Cancer research 1990;50(16):5072-6.
1990: Y Skornick; Suzanne Topalian; STEVEN ROSENBERG
Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor.
Journal of biological response modifiers 1990;9(4):431-8.
1990: G J Hauser; J K McIntosh; William D Travis; STEVEN ROSENBERG
Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
Cancer research 1990;50(12):3503-8.
1990: M T Lotze; Mary Custer; E S Bolton; E A Wiebke; Y Kawakami; STEVEN ROSENBERG
Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.
Human immunology 1990;28(2):198-207.
1990: Suzanne Topalian; A Kasid; STEVEN ROSENBERG
Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(11):4487-95.
1990: A Eisenthal; R B Cameron; STEVEN ROSENBERG
Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(11):4463-71.
1990: J S Weber; STEVEN ROSENBERG
Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes.
Journal of the National Cancer Institute 1990;82(9):755-61.
1990: A H Kragel; William D Travis; L Feinberg; S Pittaluga; L M Striker; W C Roberts; M T Lotze; J J Yang; STEVEN ROSENBERG
Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients.
Human pathology 1990;21(5):493-502.
1990: STEVEN ROSENBERG
Adoptive immunotherapy for cancer.
Scientific American 1990;262(5):62-9.
1990: D Jablons; E Bolton; S Mertins; M Rubin; PA Pizzo; STEVEN ROSENBERG; M T Lotze
IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(9):3630-6.
1990: J K McIntosh; James J Mulé; William D Travis; STEVEN ROSENBERG
Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
Cancer research 1990;50(8):2463-9.
1990: E A Wiebke; Mary Custer; STEVEN ROSENBERG; M T Lotze
Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Journal of biological response modifiers 1990;9(2):113-26.
1990: J C Yang; Donna Perry-Lalley; STEVEN ROSENBERG
An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
Journal of biological response modifiers 1990;9(2):149-59.
1990: C M Huang; Ronald J Elin; M Ruddel; C Sliva; M T Lotze; STEVEN ROSENBERG
Changes in laboratory results for cancer patients treated with interleukin-2.
Clinical chemistry 1990;36(3):431-4.
1990: James J Mulé; J K McIntosh; D M Jablons; STEVEN ROSENBERG
Antitumor activity of recombinant interleukin 6 in mice.
The Journal of experimental medicine 1990;171(3):629-36.
1990: R A Knazek; Y W Wu; P M Aebersold; STEVEN ROSENBERG
Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors.
Journal of immunological methods 1990;127(1):29-37.
1990: R J Barth; S N Bock; James J Mulé; STEVEN ROSENBERG
Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(4):1531-7.
1990: Suzanne Topalian; STEVEN ROSENBERG
Cellular immunotherapy of cancer.
Critical care medicine 1990;18(2 Suppl):S144.
1990: R B Cameron; Paul J Spiess; STEVEN ROSENBERG
Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.
The Journal of experimental medicine 1990;171(1):249-63.
1990: Suzanne Topalian; STEVEN ROSENBERG
Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
Important advances in oncology 1990;():19-41.
1990: Gabriel P Haas; D Solomon; STEVEN ROSENBERG
Tumor-infiltrating lymphocytes from nonrenal urological malignancies.
Cancer immunology, immunotherapy : CII 1990;30(6):342-50.
1990: A Belldegrun; A Kasid; M Uppenkamp; STEVEN ROSENBERG
Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid.
Cancer immunology, immunotherapy : CII 1990;31(1):1-10.
1990: P Aebersold; A Kasid; STEVEN ROSENBERG
Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.
Human gene therapy 1990;1(4):373-84.
1989: Joshua Rubin; L J Elwood; STEVEN ROSENBERG; M T Lotze
Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Cancer research 1989;49(24 Pt 1):7086-92.
1989: A Eisenthal; STEVEN ROSENBERG
Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
Cancer research 1989;49(24 Pt 1):6953-9.
1989: STEVEN ROSENBERG; M T Lotze; J C Yang; W Marston Linehan; Claudia A Seipp; S Calabro; S E Karp; R M Sherry; S Steinberg; Donald E White
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1863-74.
1989: Bernard Fisher; A M Keenan; B S Garra; Seth M Steinberg; Donald E White; A M DiBisceglie; Jay H Hoofnagle; P Yolles; STEVEN ROSENBERG; M T Lotze
Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1852-62.
1989: K D Griffith; Elizabeth J Read; Jorge Carrasquillo; Charles S Carter; J C Yang; Bernard Fisher; P Aebersold; B S Packard; M Y Yu; STEVEN ROSENBERG
In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
Journal of the National Cancer Institute 1989;81(22):1709-17.
1989: T Andrew Lister; D Crowther; S B Sutcliffe; E Glatstein; George P Canellos; R C Young; STEVEN ROSENBERG; C A Coltman; M Tubiana
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1630-6.
1989: STEVEN ROSENBERG; M T Lotze; J C Yang; P M Aebersold; W Marston Linehan; Claudia A Seipp; Donald E White
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Annals of surgery 1989;210(4):474-84; discussion 484-5.
1989: S C Saris; Nicholas Patronas; STEVEN ROSENBERG; J T Alexander; J Frank; Douglas J Schwartzentruber; Joshua Rubin; D Barba; Edward H Oldfield
The effect of intravenous interleukin-2 on brain water content.
Journal of neurosurgery 1989;71(2):169-74.
1989: E E Lack; Seth M Steinberg; Donald E White; T Kinsella; E Glatstein; Alfred E Chang; STEVEN ROSENBERG
Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas.
Journal of surgical oncology 1989;41(4):263-73.
1989: J C Yang; STEVEN ROSENBERG
Surgery for adult patients with soft tissue sarcomas.
Seminars in oncology 1989;16(4):289-96.
1989: Kirk D Denicoff; T M Durkin; M T Lotze; P E Quinlan; C L Davis; Samuel J Listwak; STEVEN ROSENBERG; David Rubinow
The neuroendocrine effects of interleukin-2 treatment.
The Journal of clinical endocrinology and metabolism 1989;69(2):402-10.
1989: J A Krosnick; James J Mulé; J K McIntosh; STEVEN ROSENBERG
Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Cancer research 1989;49(14):3729-33.
1989: A Kasid; E P Director; STEVEN ROSENBERG
Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(2):736-9.
1989: J K McIntosh; D M Jablons; James J Mulé; R P Nordan; Stuart Rudikoff; M T Lotze; STEVEN ROSENBERG
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(1):162-7.
1989: A Belldegrun; A Kasid; M Uppenkamp; Suzanne Topalian; STEVEN ROSENBERG
Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(12):4520-6.
1989: STEVEN ROSENBERG
Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.
Cancer treatment reviews 1989;16 Suppl A():115-21.
1989: Suzanne Topalian; D Solomon; STEVEN ROSENBERG
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3714-25.
1989: Y Kawakami; Mary Custer; STEVEN ROSENBERG; M T Lotze
IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3452-61.
1989: D Jablons; Seth M Steinberg; J Roth; S Pittaluga; STEVEN ROSENBERG; Harvey I Pass
Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators.
The Journal of thoracic and cardiovascular surgery 1989;97(5):695-705.
1989: A Eisenthal; STEVEN ROSENBERG
The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(7):2307-13.
1989: J K McIntosh; James J Mulé; J A Krosnick; STEVEN ROSENBERG
Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
Cancer research 1989;49(6):1408-14.
1989: A Belldegrun; D E Webb; HA Austin; Seth M Steinberg; W Marston Linehan; STEVEN ROSENBERG
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.
The Journal of urology 1989;141(3):499-503.
1989: D M Jablons; James J Mulé; J K McIntosh; P B Sehgal; L T May; C M Huang; STEVEN ROSENBERG; M T Lotze
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(5):1542-7.
1989: H Stötter; E A Wiebke; S Tomita; A Belldegrun; Suzanne Topalian; STEVEN ROSENBERG; M T Lotze
Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(5):1767-73.
1989: Raj K Puri; William D Travis; STEVEN ROSENBERG
Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Cancer research 1989;49(4):969-76.
1989: Bernard Fisher; B S Packard; Elizabeth J Read; Jorge Carrasquillo; Charles S Carter; Suzanne Topalian; J C Yang; P Yolles; Steven M Larson; STEVEN ROSENBERG
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):250-61.
1989: D Barba; S C Saris; C Holder; STEVEN ROSENBERG; Edward H Oldfield
Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Journal of neurosurgery 1989;70(2):175-82.
1989: James J Mulé; J A Krosnick; STEVEN ROSENBERG
IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(2):726-33.
1989: Fox Bernard; STEVEN ROSENBERG
Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Cancer immunology, immunotherapy : CII 1989;29(3):155-66.
1989: A L Asher; James J Mulé; STEVEN ROSENBERG
Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells.
Cancer immunology, immunotherapy : CII 1989;28(2):153-6.
1989: R E Lee; M T Lotze; J M Skibber; E Tucker; R O Bonow; Frederick P Ognibene; Jorge Carrasquillo; James H Shelhamer; J E Parrillo; STEVEN ROSENBERG
Cardiorespiratory effects of immunotherapy with interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):7-20.
1989: Alfred E Chang; STEVEN ROSENBERG
Overview of interleukin-2 as an immunotherapeutic agent.
Seminars in surgical oncology 1989;5(6):385-90.
1989: J A Krosnick; J K McIntosh; James J Mulé; STEVEN ROSENBERG
Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.
Cancer immunology, immunotherapy : CII 1989;30(3):133-8.
1989: A Belldegrun; STEVEN ROSENBERG
Adoptive immunotherapy of urologic tumors.
Cancer treatment and research 1989;46():213-33.
1989: Raj K Puri; STEVEN ROSENBERG
Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.
Cancer immunology, immunotherapy : CII 1989;28(4):267-74.
1989: J J Mulé; STEVEN ROSENBERG
Immunotherapy with lymphokine combinations.
Important advances in oncology 1989;():99-126.
1988: STEVEN ROSENBERG; B S Packard; P M Aebersold; D Solomon; Suzanne Topalian; S T Toy; P Simon; M T Lotze; J C Yang; Claudia A Seipp
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
The New England journal of medicine 1988;319(25):1676-80.
1988: A Eisenthal; R B Cameron; I Uppenkamp; STEVEN ROSENBERG
Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Cancer research 1988;48(24 Pt 1):7140-5.
1988: Y Kawakami; STEVEN ROSENBERG; M T Lotze
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.
The Journal of experimental medicine 1988;168(6):2183-91.
1988: R E Lee; Anthony Gaspari; M T Lotze; Alfred E Chang; STEVEN ROSENBERG
Interleukin 2 and psoriasis.
Archives of dermatology 1988;124(12):1811-5.
1988: Douglas J Schwartzentruber; M T Lotze; STEVEN ROSENBERG
Colonic perforation. An unusual complication of therapy with high-dose interleukin-2.
Cancer 1988;62(11):2350-3.
1988: STEVEN ROSENBERG; Susan L Schwarz; Paul J Spiess
Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
Journal of the National Cancer Institute 1988;80(17):1393-7.
1988: R B Cameron; J K McIntosh; STEVEN ROSENBERG
Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cancer research 1988;48(20):5810-7.
1988: J S Weber; STEVEN ROSENBERG
Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Cancer research 1988;48(20):5818-24.
1988: Frederick P Ognibene; STEVEN ROSENBERG; M Lotze; J Skibber; M M Parker; James H Shelhamer; J E Parrillo
Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.
Chest 1988;94(4):750-4.
1988: A Eisenthal; STEVEN ROSENBERG
Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.
Clinical & experimental metastasis 1988;6(5):387-400.
1988: D E Webb; HA Austin; A Belldegrun; E Vaughan; W Marston Linehan; STEVEN ROSENBERG
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
Clinical nephrology 1988;30(3):141-5.
1988: E A Wiebke; STEVEN ROSENBERG; M T Lotze
Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(9):1440-9.
1988: A Eisenthal; Eitan Shiloni; STEVEN ROSENBERG
Characterization of IL-2-induced murine cells which exhibit ADCC activity.
Cellular immunology 1988;115(2):257-72.
1988: P Aebersold; Charles S Carter; C Hyatt; S Johnson; K Ottaway; Susan F Leitman; STEVEN ROSENBERG
A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials.
Journal of immunological methods 1988;112(1):1-7.
1988: STEVEN ROSENBERG
The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Annals of surgery 1988;208(2):121-35.
1988: J K McIntosh; James J Mulé; Maria J Merino; STEVEN ROSENBERG
Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
Cancer research 1988;48(14):4011-7.
1988: S C Saris; STEVEN ROSENBERG; R B Friedman; Joshua Rubin; D Barba; Edward H Oldfield
Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.
Journal of neurosurgery 1988;69(1):29-34.
1988: STEVEN ROSENBERG; M T Lotze; James J Mulé
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
Annals of internal medicine 1988;108(6):853-64.
1988: A T LeFor; A Eisenthal; STEVEN ROSENBERG
Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(11):4062-9.
1988: C Simpson; Claudia A Seipp; STEVEN ROSENBERG
The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.
Seminars in oncology nursing 1988;4(2):132-41.
1988: S E Ettinghausen; R K Puri; STEVEN ROSENBERG
Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
Journal of the National Cancer Institute 1988;80(3):177-88.
1988: RS Cotran; J S Pober; Michael A Gimbrone; Timothy A Springer; E A Wiebke; Anthony Gaspari; STEVEN ROSENBERG; M T Lotze
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(6):1883-8.
1988: STEVEN ROSENBERG
Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):403-6.
1988: M T Lotze; STEVEN ROSENBERG
The immunologic treatment of cancer.
CA: a cancer journal for clinicians 1988;38(2):68-94.
1988: STEVEN ROSENBERG
Immunotherapy of cancer using interleukin 2: current status and future prospects.
Immunology today 1988;9(2):58-62.
1988: K A Kern; Arturo Brunetti; J A Norton; Alfred E Chang; M Malawer; E Lack; R D Finn; STEVEN ROSENBERG; Steven M Larson
Metabolic imaging of human extremity musculoskeletal tumors by PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(2):181-6.
1988: Charles S Carter; Susan F Leitman; H Cullis; L M Muul; K Nason-Burchenal; STEVEN ROSENBERG; HARVEY KLEIN
Technical aspects of lymphokine-activated killer cell production.
Journal of clinical apheresis 1988;4(2-3):113-7.
1988: James J Mulé; A Asher; J McIntosh; R Lafreniere; Eitan Shiloni; A Lefor; C M Reichert; STEVEN ROSENBERG
Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy.
Cancer immunology, immunotherapy : CII 1988;26(3):202-8.
1988: STEVEN ROSENBERG
Development of new immunologic approaches to cancer therapy.
Blood purification 1988;6(2):69-76.
1988: T J Kinsella; W F Sindelar; E Lack; E Glatstein; STEVEN ROSENBERG
Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(1):18-25.
1988: J C Yang; STEVEN ROSENBERG
Current approaches to the adoptive immunotherapy of cancer.
Advances in experimental medicine and biology 1988;233():459-67.
1988: A Belldegrun; I Uppenkamp; STEVEN ROSENBERG
Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
The Journal of urology 1988;139(1):150-5.
1988: A Belldegrun; L M Muul; STEVEN ROSENBERG
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Cancer research 1988;48(1):206-14.
1988: M Z Papa; J C Yang; John T Vetto; Eitan Shiloni; A Eisenthal; STEVEN ROSENBERG
Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Cancer research 1988;48(1):122-9.
1988: STEVEN ROSENBERG
Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.
Important advances in oncology 1988;():217-57.
1988: James J Mulé; Susan L Schwarz; Anita B Roberts; Michael B. Sporn; STEVEN ROSENBERG
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Cancer immunology, immunotherapy : CII 1988;26(2):95-100.
1987: L M Muul; K Nason-Burchenal; C Hyatt; S Schwarz; D Slavin; E P Director; STEVEN ROSENBERG
Studies of serum-free culture medium in the generation of lymphokine activated killer cells.
Journal of immunological methods 1987;105(2):183-92.
1987: J S Weber; G Jay; K Tanaka; STEVEN ROSENBERG
Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.
The Journal of experimental medicine 1987;166(6):1716-33.
1987: Paul J Spiess; J C Yang; STEVEN ROSENBERG
In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Journal of the National Cancer Institute 1987;79(5):1067-75.
1987: P J Cohen; M T Lotze; J R Roberts; STEVEN ROSENBERG; Elaine S Jaffe
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.
The American journal of pathology 1987;129(2):208-16.
1987: Anthony Gaspari; M T Lotze; STEVEN ROSENBERG; J B Stern; S I Katz
Dermatologic changes associated with interleukin 2 administration.
JAMA : the journal of the American Medical Association 1987;258(12):1624-9.
1987: J M Skibber; M T Lotze; C A Seipp; R Salcedo; STEVEN ROSENBERG
Limb-sparing surgery for soft tissue sarcomas: wound related morbidity in patients undergoing wide local excision.
Surgery 1987;102(3):447-52.
1987: J J Mulé; C A Smith; STEVEN ROSENBERG
Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.
The Journal of experimental medicine 1987;166(3):792-7.
1987: K D Denicoff; David Rubinow; M Z Papa; C Simpson; Claudia A Seipp; M T Lotze; Alfred E Chang; Donald Rosenstein; STEVEN ROSENBERG
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.
Annals of internal medicine 1987;107(3):293-300.
1987: Suzanne Topalian; L M Muul; D Solomon; STEVEN ROSENBERG
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
Journal of immunological methods 1987;102(1):127-41.
1987: K Roberts; M T Lotze; STEVEN ROSENBERG
Separation and functional studies of the human lymphokine-activated killer cell.
Cancer research 1987;47(16):4366-71.
1987: L M Muul; K Nason-Burchenal; Charles S Carter; H Cullis; D Slavin; C Hyatt; E P Director; Susan F Leitman; HARVEY KLEIN; STEVEN ROSENBERG
Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.
Journal of immunological methods 1987;101(2):171-81.
1987: W G McKenna; M M Barnes; T J Kinsella; STEVEN ROSENBERG; E E Lack; E Glatstein
Combined modality treatment of adult soft tissue sarcomas of the head and neck.
International journal of radiation oncology, biology, physics 1987;13(8):1127-33.
1987: STEVEN ROSENBERG
Combined treatment approaches to soft tissue sarcomas.
Hospital practice (Office ed.) 1987;22(7):151-9, 162-6.
1987: Charles S Carter; Susan F Leitman; H Cullis; L M Muul; K Nason-Burchenal; STEVEN ROSENBERG; HARVEY KLEIN
Use of a continuous-flow cell separator in density gradient isolation of lymphocytes.
Transfusion 1987;27(4):362-5.
1987: J J Mulé; J C Yang; R L Afreniere; S Y Shu; STEVEN ROSENBERG
Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(1):285-94.
1987: S Y Shu; T Chou; STEVEN ROSENBERG
Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(1):295-304.
1987: S E Ettinghausen; J G Moore; Donald E White; L Platanias; N S Young; STEVEN ROSENBERG
Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.
Blood 1987;69(6):1654-60.
1987: A Belldegrun; D E Webb; HA Austin; Seth M Steinberg; D E White; W Marston Linehan; STEVEN ROSENBERG
Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.
Annals of internal medicine 1987;106(6):817-22.
1987: A Eisenthal; R Lafreniere; A T Lefor; STEVEN ROSENBERG
Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
Cancer research 1987;47(11):2771-6.
1987: S B Edge; W K Funkhouser; A Berman; Claudia A Seipp; A Tanner; R Wesley; STEVEN ROSENBERG; Alfred E Chang
High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study.
American journal of clinical oncology 1987;10(3):257-63.
1987: J M Skibber; M T Lotze; I Uppenkamp; W Ross; STEVEN ROSENBERG
Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer.
The Journal of surgical research 1987;42(6):613-21.
1987: M T Lotze; K Roberts; M C Custer; D A Segal; STEVEN ROSENBERG
Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.
The Journal of surgical research 1987;42(5):580-9.
1987: Y L Matory; Alfred E Chang; E H Lipford; Rita M Braziel; C L Hyatt; STEVEN ROSENBERG
The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
Journal of the National Medical Association 1987;79(5):537-41.
1987: M T Lotze; M C Custer; S O Sharrow; L A Rubin; D L Nelson; STEVEN ROSENBERG
In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Cancer research 1987;47(8):2188-95.
1987: STEVEN ROSENBERG; M T Lotze; L M Muul; Alfred E Chang; F P Avis; Susan F Leitman; W Marston Linehan; C N Robertson; R E Lee; Joshua Rubin
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
The New England journal of medicine 1987;316(15):889-97.
1987: Eitan Shiloni; A Eisenthal; D Sachs; STEVEN ROSENBERG
Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(6):1992-8.
1987: D H Lynch; D J Weiland; STEVEN ROSENBERG; Richard J Hodes
Different specificities of cloned T cells assessed by in vitro proliferation assays and by the ability to mediate skin graft rejection in vivo.
Transplantation 1987;43(3):408-11.
1987: John T Vetto; M Z Papa; M T Lotze; Alfred E Chang; STEVEN ROSENBERG
Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(3):496-503.
1987: S Shu; T Chou; STEVEN ROSENBERG
In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Cancer research 1987;47(5):1354-60.
1987: Anthony Fauci; STEVEN ROSENBERG; S A Sherwin; C A Dinarello; Dan Longo; H Clifford Lane
NIH conference. Immunomodulators in clinical medicine.
Annals of internal medicine 1987;106(3):421-33.
1987: A Asher; James J Mulé; C M Reichert; Eitan Shiloni; STEVEN ROSENBERG
Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(3):963-74.
1987: R T Ottow; E P Steller; P H Sugarbaker; R A Wesley; STEVEN ROSENBERG
Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models.
Cellular immunology 1987;104(2):366-76.
1987: L M Muul; P J Spiess; E P Director; STEVEN ROSENBERG
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(3):989-95.
1987: L A Matis; M Bookman; STEVEN ROSENBERG
Cloning with antigens and interleukin 2 of murine T lymphocytes having distinct functions.
Methods in enzymology 1987;150():342-51.
1987: James J Mulé; STEVEN ROSENBERG
Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2.
Progress in clinical and biological research 1987;244():79-91.
1987: Suzanne Topalian; STEVEN ROSENBERG
Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Acta haematologica 1987;78 Suppl 1():75-6.
1987: J M Skibber; M T Lotze; L M Muul; I K Uppenkamp; W Ross; STEVEN ROSENBERG
Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.
Natural immunity and cell growth regulation 1987;6(6):291-305.
1987: STEVEN ROSENBERG
ABVD versus MOPP: which is better?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):7.
1986: M T Lotze; Y L Matory; A A Rayner; S E Ettinghausen; John T Vetto; Claudia A Seipp; STEVEN ROSENBERG
Clinical effects and toxicity of interleukin-2 in patients with cancer.
Cancer 1986;58(12):2764-72.
1986: M T Lotze; Alfred E Chang; Claudia A Seipp; C Simpson; John T Vetto; STEVEN ROSENBERG
High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.
JAMA : the journal of the American Medical Association 1986;256(22):3117-24.
1986: S E Ettinghausen; R O Bonow; S T Palmeri; Claudia A Seipp; S M Steinberg; D E White; STEVEN ROSENBERG
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(12):1445-51.
1986: M T Lotze; M C Custer; STEVEN ROSENBERG
Intraperitoneal administration of interleukin-2 in patients with cancer.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(12):1373-9.
1986: R Lafreniere; M S Rosenstein; STEVEN ROSENBERG
Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
Journal of immunological methods 1986;94(1-2):37-49.
1986: W E Rizzoni; Harvey I Pass; M N Wesley; STEVEN ROSENBERG; J A Roth
Resection of recurrent pulmonary metastases in patients with soft-tissue sarcomas.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(11):1248-52.
1986: Claudia A Seipp; C Simpson; STEVEN ROSENBERG
Clinical trials with IL-2.
Oncology nursing forum 1986;13(6):25-9.
1986: Eitan Shiloni; R Lafreniere; James J Mulé; Susan L Schwarz; STEVEN ROSENBERG
Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Cancer research 1986;46(11):5633-40.
1986: M Z Papa; John T Vetto; S E Ettinghausen; James J Mulé; STEVEN ROSENBERG
Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
Cancer research 1986;46(11):5618-23.
1986: P A Henkart; C C Yue; J Yang; STEVEN ROSENBERG
Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(8):2611-7.
1986: M Z Papa; J J Mulé; STEVEN ROSENBERG
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Cancer research 1986;46(10):4973-8.
1986: STEVEN ROSENBERG; P Spiess; R Lafreniere
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
Science (New York, N.Y.) 1986;233(4770):1318-21.
1986: S T Palmeri; R O Bonow; C E Myers; Claudia A Seipp; J Jenkins; M V Green; S L Bacharach; STEVEN ROSENBERG
Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
The American journal of cardiology 1986;58(7):607-13.
1986: STEVEN ROSENBERG
MOPP after two decades.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(9):1289-90.
1986: M Rosenstein; S E Ettinghausen; STEVEN ROSENBERG
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(5):1735-42.
1986: M T Lotze; STEVEN ROSENBERG
Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Immunobiology 1986;172(3-5):420-37.
1986: STEVEN ROSENBERG; M T Lotze; L M Muul; Susan F Leitman; Alfred E Chang; John T Vetto; Claudia A Seipp; C Simpson
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
Surgery 1986;100(2):262-72.
1986: J C Yang; J J Mulé; STEVEN ROSENBERG
Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(2):715-22.
1986: D A Potter; T Kinsella; E Glatstein; R Wesley; Donald E White; Claudia A Seipp; Alfred E Chang; E E Lack; J Costa; STEVEN ROSENBERG
High-grade soft tissue sarcomas of the extremities.
Cancer 1986;58(1):190-205.
1986: Alfred E Chang; S Y Shu; T Chou; R Lafreniere; STEVEN ROSENBERG
Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.
Cancer research 1986;46(7):3426-30.
1986: STEVEN ROSENBERG
The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Seminars in oncology 1986;13(2):200-6.
1986: S E Ettinghausen; STEVEN ROSENBERG
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Cancer research 1986;46(6):2784-92.
1986: S Shu; T Chou; STEVEN ROSENBERG
In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(10):3891-8.
1986: J J Mulé; J Yang; S Shu; STEVEN ROSENBERG
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(10):3899-909.
1986: David N Danforth; P A Findlay; H D McDonald; Marc Lippman; C M Reichert; T d'Angelo; C R Gorrell; N L Gerber; A S Lichter; STEVEN ROSENBERG
Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(5):655-62.
1986: L A Matis; S Shu; E S Groves; S Zinn; T Chou; A M Kruisbeek; M Rosenstein; STEVEN ROSENBERG
Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(9):3496-501.
1986: L M Muul; E P Director; C L Hyatt; STEVEN ROSENBERG
Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.
Journal of immunological methods 1986;88(2):265-75.
1986: V T DeVita; Marc Lippman; S M Hubbard; D C Ihde; STEVEN ROSENBERG
The effect of combined modality therapy on local control and survival.
International journal of radiation oncology, biology, physics 1986;12(4):487-501.
1986: R Lafreniere; STEVEN ROSENBERG
A novel approach to the generation and identification of experimental hepatic metastases in a murine model.
Journal of the National Cancer Institute 1986;76(2):309-22.
1986: James J Mulé; S E Ettinghausen; Paul J Spiess; S Shu; STEVEN ROSENBERG
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Cancer research 1986;46(2):676-83.
1986: M T Lotze; STEVEN ROSENBERG
Protocol design for lymphokine testing in clinical studies of human cancer.
Lymphokine research 1986;5 Suppl 1():S177-81.
1986: S E Ettinghausen; STEVEN ROSENBERG
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Springer seminars in immunopathology 1986;9(1):51-71.
1986: STEVEN ROSENBERG; M T Lotze
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Annual review of immunology 1986;4():681-709.
1986: STEVEN ROSENBERG
Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Important advances in oncology 1986;():55-91.
1985: STEVEN ROSENBERG; M T Lotze; L M Muul; Susan F Leitman; Alfred E Chang; S E Ettinghausen; Y L Matory; J M Skibber; Eitan Shiloni; John T Vetto
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
The New England journal of medicine 1985;313(23):1485-92.
1985: R Lafreniere; STEVEN ROSENBERG
Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(6):4273-80.
1985: S E Ettinghausen; E H Lipford; James J Mulé; STEVEN ROSENBERG
Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(5):3623-35.
1985: G L Andriole; J J Mulé; C T Hansen; W M Linehan; STEVEN ROSENBERG
Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(5):2911-3.
1985: T A Sharp; R E Gress; D H Sachs; STEVEN ROSENBERG
Assessment of mixed lymphocyte reactivity in human bone marrow cell cultures.
Transplantation 1985;40(5):551-6.
1985: STEVEN ROSENBERG
Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
Journal of the National Cancer Institute 1985;75(4):595-603.
1985: M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; Claudia A Seipp; M C Custer; STEVEN ROSENBERG
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(4):2865-75.
1985: S Shu; STEVEN ROSENBERG
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(4):2895-903.
1985: E Shapiro; T J Kinsella; R W Makuch; Benedick A Fraass; E Glatstein; STEVEN ROSENBERG; R J Sherins
Effects of fractionated irradiation of endocrine aspects of testicular function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(9):1232-9.
1985: STEVEN ROSENBERG; J J Mulé
Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Surgery 1985;98(3):437-44.
1985: R Lafreniere; STEVEN ROSENBERG
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Cancer research 1985;45(8):3735-41.
1985: S E Ettinghausen; E H Lipford; James J Mulé; STEVEN ROSENBERG
Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(2):1488-97.
1985: Y L Matory; Alfred E Chang; E H Lipford; Rita M Braziel; C L Hyatt; H D McDonald; STEVEN ROSENBERG
Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.
Journal of biological response modifiers 1985;4(4):377-90.
1985: H Kawamura; STEVEN ROSENBERG; J A Berzofsky
Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.
The Journal of experimental medicine 1985;162(1):381-6.
1985: J J Mulé; S Shu; STEVEN ROSENBERG
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(1):646-52.
1985: A A Rayner; E A Grimm; M T Lotze; D J Wilson; STEVEN ROSENBERG
Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
Journal of the National Cancer Institute 1985;75(1):67-75.
1985: STEVEN ROSENBERG
Combined modality therapy of cancer. What is it and when does it work?
The New England journal of medicine 1985;312(23):1512-4.
1985: STEVEN ROSENBERG; Claudia A Seipp; Donald E White; R Wesley
Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(5):698-709.
1985: STEVEN ROSENBERG; James J Mulé; Paul J Spiess; C M Reichert; Susan L Schwarz
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
The Journal of experimental medicine 1985;161(5):1169-88.
1985: S Y Shu; STEVEN ROSENBERG
Adoptive immunotherapy of newly induced murine sarcomas.
Cancer research 1985;45(4):1657-62.
1985: D H Lynch; R E Gress; B W Needleman; STEVEN ROSENBERG; Richard J Hodes
T cell responses to Mls determinants are restricted by cross-reactive MHC determinants.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(4):2071-8.
1985: A A Rayner; E A Grimm; M T Lotze; E W Chu; STEVEN ROSENBERG
Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Cancer 1985;55(6):1327-33.
1985: J A Roth; J B Putnam; M N Wesley; STEVEN ROSENBERG
Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients.
Cancer 1985;55(6):1361-6.
1985: STEVEN ROSENBERG
The changing approach to cancer surgery.
Hospital practice (Office ed.) 1985;20(3):105-7, 113, 116-7 passim.
1985: C M Reichert; M Rosenstein; J Von Glatz; S M Hsu; STEVEN ROSENBERG
Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Laboratory investigation; a journal of technical methods and pathology 1985;52(3):304-13.
1985: D A Potter; J Glenn; T Kinsella; E Glatstein; E E Lack; C Restrepo; Donald E White; Claudia A Seipp; R Wesley; STEVEN ROSENBERG
Patterns of recurrence in patients with high-grade soft-tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(3):353-66.
1985: J J Mulé; M Rosenstein; S Shu; STEVEN ROSENBERG
Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s).
Cancer research 1985;45(2):526-31.
1985: Y Kaufmann; M Moscovitch; R J Robb; STEVEN ROSENBERG; G Berke
Antigen/mitogen induced cytolytic activity and IL-2 secretion in memory-like CTL-hybridomas.
Advances in experimental medicine and biology 1985;184():535-50.
1985: STEVEN ROSENBERG
Adjuvant chemotherapy of adult patients with soft tissue sarcomas.
Important advances in oncology 1985;():273-94.
1985: Alfred E Chang; M T Lotze; R S Ames; J A Roth; STEVEN ROSENBERG
A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma.
Journal of immunopharmacology 1985;7(1):17-31.
1985: M T Lotze; L W Frana; S O Sharrow; R J Robb; STEVEN ROSENBERG
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(1):157-66.
1985: D P Schreiber; C Jacobs; STEVEN ROSENBERG; R S Cox; R T Hoppe
The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas.
International journal of radiation oncology, biology, physics 1985;11(1):31-6.
1984: Y Kaufmann; Alfred E Chang; R J Robb; STEVEN ROSENBERG
Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas.
Journal of immunology (Baltimore, Md. : 1950) 1984;133(6):3107-11.
1984: STEVEN ROSENBERG
Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Journal of biological response modifiers 1984;3(5):501-11.
1984: Alfred E Chang; C L Hyatt; STEVEN ROSENBERG
Systemic administration of recombinant human interleukin-2 in mice.
Journal of biological response modifiers 1984;3(5):561-72.
1984: M T Lotze; R J Robb; S O Sharrow; L W Frana; STEVEN ROSENBERG
Systemic administration of interleukin-2 in humans.
Journal of biological response modifiers 1984;3(5):475-82.
1984: James J Mulé; S Shu; Susan L Schwarz; STEVEN ROSENBERG
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Science (New York, N.Y.) 1984;225(4669):1487-9.
1984: STEVEN ROSENBERG
Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas.
Cancer treatment reports 1984;68(9):1067-78.
1984: Y Kaufmann; STEVEN ROSENBERG
Blocking by cyclosporine of antigen-induced maturation and lymphokine secretion by cytotoxic T lymphocyte hybridomas.
Transplantation 1984;38(2):148-51.
1984: M H Lampert; L H Gerber; E Glatstein; STEVEN ROSENBERG; J V Danoff
Soft tissue sarcoma: functional outcome after wide local excision and radiation therapy.
Archives of physical medicine and rehabilitation 1984;65(8):477-80.
1984: Steven M Keller; R C Rosenbaum; STEVEN ROSENBERG
The significance of bone scan abnormalities in patients with primary osteogenic sarcoma.
Journal of surgical oncology 1984;26(2):122-9.
1984: STEVEN ROSENBERG
The organization of surgical oncology in university departments of surgery.
Surgery 1984;95(5):632-4.
1984: M Rosenstein; STEVEN ROSENBERG
Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
Journal of the National Cancer Institute 1984;72(5):1161-5.
1984: M Rosenstein; I Yron; Y Kaufmann; STEVEN ROSENBERG
Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Cancer research 1984;44(5):1946-53.
1984: T G Sharp; D H Sachs; J G Matthews; J Maples; J N Woody; STEVEN ROSENBERG
Harvest of human bone marrow directly from bone.
Journal of immunological methods 1984;69(2):187-95.
1984: J H Donohue; M T Lotze; R J Robb; M Rosenstein; Rita M Braziel; E S Jaffe; STEVEN ROSENBERG
In vivo administration of purified Jurkat-derived interleukin 2 in mice.
Cancer research 1984;44(4):1380-6.
1984: J H Donohue; M Rosenstein; Alfred E Chang; M T Lotze; R J Robb; STEVEN ROSENBERG
The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(4):2123-8.
1984: M Rosenstein; T J Eberlein; STEVEN ROSENBERG
Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(4):2117-22.
1984: STEVEN ROSENBERG; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.
Science (New York, N.Y.) 1984;223(4643):1412-4.
1984: A Mazumder; T J Eberlein; E A Grimm; D J Wilson; A M Keenan; R Aamodt; STEVEN ROSENBERG
Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells.
Cancer 1984;53(4):896-905.
1984: J B Putnam; J A Roth; M N Wesley; M R Johnston; STEVEN ROSENBERG
Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas.
The Journal of thoracic and cardiovascular surgery 1984;87(2):260-8.
1984: J Costa; R A Wesley; E Glatstein; STEVEN ROSENBERG
The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.
Cancer 1984;53(3):530-41.
1984: M W Flye; G Woltering; STEVEN ROSENBERG
Aggressive pulmonary resection for metastatic osteogenic and soft tissue sarcomas.
The Annals of thoracic surgery 1984;37(2):123-7.
1984: A Mazumder; STEVEN ROSENBERG
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
The Journal of experimental medicine 1984;159(2):495-507.
1984: Dan Longo; R G Steis; H Clifford Lane; M T Lotze; STEVEN ROSENBERG; O Preble; H Masur; A H Rook; Anthony Fauci; J Jacob
Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results.
Annals of the New York Academy of Sciences 1984;437():421-30.
1984: STEVEN ROSENBERG
Adoptive immunotherapy of cancer: accomplishments and prospects.
Cancer treatment reports 1984;68(1):233-55.
1984: E A Grimm; B M Vose; E W Chu; D J Wilson; M T Lotze; A A Rayner; STEVEN ROSENBERG
The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.
Cancer immunology, immunotherapy : CII 1984;17(2):83-9.
1983: A Mazumder; M Rosenstein; STEVEN ROSENBERG
Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes.
Cancer research 1983;43(12 Pt 1):5729-34.
1983: J B Putnam; J A Roth; M N Wesley; M R Johnston; STEVEN ROSENBERG
Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors.
The Annals of thoracic surgery 1983;36(5):516-23.
1983: B Kim; M Rosenstein; D Weiland; T J Eberlein; STEVEN ROSENBERG
Clonal analysis of the lymphoid cells mediating skin allograft rejection. Mediation of graft rejection in vivo by cloned Lyt-1+2- proliferative, noncytotoxic long-term cell lines.
Transplantation 1983;36(5):525-32.
1983: E A Grimm; R J Robb; J A Roth; L M Neckers; L B Lachman; D J Wilson; STEVEN ROSENBERG
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
The Journal of experimental medicine 1983;158(4):1356-61.
1983: W F Sindelar; T Kinsella; Joel E Tepper; E L Travis; STEVEN ROSENBERG; E Glatstein
Experimental and clinical studies with intraoperative radiotherapy.
Surgery, gynecology & obstetrics 1983;157(3):205-19.
1983: M A Duncan; M T Lotze; L H Gerber; STEVEN ROSENBERG
Incidence, recovery, and management of serratus anterior muscle palsy after axillary node dissection.
Physical therapy 1983;63(8):1243-7.
1983: STEVEN ROSENBERG; Joel E Tepper; E Glatstein; J Costa; R Young; A Baker; Murray F Brennan; E V Demoss; Claudia A Seipp; W F Sindelar; P Sugarbaker; R Wesley
Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities.
Cancer 1983;52(3):424-34.
1983: M Rosenstein; T Eberlein; S Schwarz; STEVEN ROSENBERG
Simplified techniques for the isolation of alloreactive cell lines and clones with specific cytotoxic or proliferative activity.
Journal of immunological methods 1983;61(2):183-93.
1983: A Dresdale; R O Bonow; R Wesley; S T Palmeri; L Barr; D Mathison; T D'Angelo; STEVEN ROSENBERG
Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
Cancer 1983;52(1):51-60.
1983: STEVEN ROSENBERG; P J Spiess; S Schwarz
In vivo administration of Interleukin-2 enhances specific alloimmune responses.
Transplantation 1983;35(6):631-4.
1983: J H Donohue; STEVEN ROSENBERG
The fate of interleukin-2 after in vivo administration.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(5):2203-8.
1983: E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; STEVEN ROSENBERG
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
The Journal of experimental medicine 1983;157(3):884-97.
1983: A Mazumder; E A Grimm; STEVEN ROSENBERG
Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(2):958-64.
1983: R Almaraz; W Ballinger; D H Sachs; STEVEN ROSENBERG
The effect of peripheral lymphoid cells on the incidence of lethal graft versus host disease following allogeneic mouse bone marrow transplantation.
The Journal of surgical research 1983;34(2):133-44.
1983: T G Sharp; D H Sachs; Anthony Fauci; Gerald L Messerschmidt; STEVEN ROSENBERG
T cell depletion of human bone marrow using monoclonal antibody and complement-mediated lysis.
Transplantation 1983;35(2):112-20.
1983: A Mazumder; E A Grimm; STEVEN ROSENBERG
Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
Cancer immunology, immunotherapy : CII 1983;15(1):1-10.
1982: A R Dresdale; L H Barr; R O Bonow; D J Mathisen; C E Myers; D E Schwartz; T d'Angelo; STEVEN ROSENBERG
Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy.
American journal of clinical oncology 1982;5(6):657-63.
1982: STEVEN ROSENBERG
Lymphoplasmapheresis in rheumatoid arthritis.
The New England journal of medicine 1982;307(20):1271.
1982: STEVEN ROSENBERG; Joel E Tepper; E Glatstein; J Costa; A Baker; Murray F Brennan; E V DeMoss; Claudia A Seipp; W F Sindelar; P Sugarbaker; R Wesley
The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.
Annals of surgery 1982;196(3):305-15.
1982: STEVEN ROSENBERG; T J Eberlein; E A Grimm; M T Lotze; A Mazumder; M Rosenstein
Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Surgery 1982;92(2):328-36.
1982: T J Eberlein; M Rosenstein; STEVEN ROSENBERG
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.
The Journal of experimental medicine 1982;156(2):385-97.
1982: T J Eberlein; M Rosenstein; P J Spiess; STEVEN ROSENBERG
Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Journal of the National Cancer Institute 1982;69(1):109-16.
1982: E A Grimm; A Mazumder; STEVEN ROSENBERG
In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor.
Cellular immunology 1982;70(2):248-59.
1982: J M Brown; P C Shoffner; S P Tondreau; E J Matthews; W D Terry; STEVEN ROSENBERG
Cytotoxic antibody reactivity in sera of melanoma patients against allogeneic and autologous cultured tumor cells and fibroblasts.
Cancer research 1982;42(6):2216-22.
1982: E A Grimm; A Mazumder; H Z Zhang; STEVEN ROSENBERG
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
The Journal of experimental medicine 1982;155(6):1823-41.
1982: A Mazumder; E A Grimm; H Z Zhang; STEVEN ROSENBERG
Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.
Cancer research 1982;42(3):913-8.
1982: Joel E Tepper; STEVEN ROSENBERG; E Glatstein
Radiation therapy technique in soft tissue sarcomas of the extremity--policies of treatment at the National Cancer Institute.
International journal of radiation oncology, biology, physics 1982;8(2):263-73.
1982: G M Gray; STEVEN ROSENBERG; A D Cooper; P B Gregory; D T Stein; H Herzenberg
Lymphomas involving the gastrointestinal tract.
Gastroenterology 1982;82(1):143-52.
1982: T J Eberlein; M Rosenstein; P Spiess; R Wesley; STEVEN ROSENBERG
Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.
Cancer immunology, immunotherapy : CII 1982;13(1):5-13.
1981: STEVEN ROSENBERG; Joel E Tepper; E Glatstein; J Costa; R Young; Claudia A Seipp; R Wesley
Adjuvant chemotherapy for patients with soft tissue sarcomas.
The Surgical clinics of North America 1981;61(6):1415-23.
1981: Richard I Fisher; W D Terry; Richard J Hodes; STEVEN ROSENBERG; R Makuch; H G Gordon; S G Fisher
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
The Surgical clinics of North America 1981;61(6):1267-77.
1981: R C Shamberger; R J Sherins; J L Ziegler; E Glatstein; STEVEN ROSENBERG
Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma.
Journal of the National Cancer Institute 1981;67(6):1213-8.
1981: M T Lotze; E A Grimm; A Mazumder; J L Strausser; STEVEN ROSENBERG
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Cancer research 1981;41(11 Pt 1):4420-5.
1981: R C Shamberger; STEVEN ROSENBERG; C A Seipp; R J Sherins
Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma.
Cancer treatment reports 1981;65(9-10):739-46.
1981: M Rosenstein; T Eberlein; M M Kemeny; P H Sugarbaker; STEVEN ROSENBERG
In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(2):566-71.
1981: J L Strausser; A Mazumder; E A Grimm; M T Lotze; STEVEN ROSENBERG
Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(1):266-71.
1981: STEVEN ROSENBERG; E J Glatstein
Perspectives on the role of surgery and radiation therapy in the treatment of soft tissue sarcomas of the extremities.
Seminars in oncology 1981;8(2):190-200.
1981: M T Lotze; STEVEN ROSENBERG
In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(6):2215-20.
1981: R C Shamberger; R J Sherins; STEVEN ROSENBERG
The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma.
Cancer 1981;47(10):2368-74.
1981: C M Reichert; STEVEN ROSENBERG; B L Weber; J Costa
Malignant melanoma: a search for occult lymph node metastases.
Human pathology 1981;12(5):449-51.
1981: STEVEN ROSENBERG
Treatment of soft tissue and bone sarcomas: review of studies at the National Cancer Institute.
National Cancer Institute monograph 1981;(56):241-4.
1981: STEVEN ROSENBERG; F S Ligler; V Ugolini; P E Lipsky
A monoclonal antibody that identifies human peripheral blood monocytes recognizes the accessory- cells required for mitogen-induced T lymphocyte proliferation.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(4):1473-7.
1981: STEVEN ROSENBERG; P E Lipsky
The role of monocytes in pokeweed mitogen-stimulated human B cell activation: separate requirements for intact monocytes and a soluble monocyte factor.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(4):1341-5.
1981: Alfred E Chang; D J Shiling; R C Stillman; Nelson H Goldberg; C A Seipp; I Barofsky; STEVEN ROSENBERG
A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
Cancer 1981;47(7):1746-51.
1981: M T Lotze; M A Duncan; L H Gerber; eugene woltering; STEVEN ROSENBERG
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study.
Annals of surgery 1981;193(3):288-95.
1981: P J Spiess; STEVEN ROSENBERG
A simplified method for the production of murine T-cell growth factor free of lectin.
Journal of immunological methods 1981;42(2):213-22.
1980: M T Lotze; Bruce R Line; D J Mathisen; STEVEN ROSENBERG
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.
Journal of immunology (Baltimore, Md. : 1950) 1980;125(4):1487-93.
1980: E H Austin; Murray F Brennan; STEVEN ROSENBERG
Effects of protein-calorie restriction on the immune response to skin allografts in the rat.
Transplantation 1980;30(3):219-25.
1980: STEVEN ROSENBERG; P J Spiess; S Schwarz
In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells.
Cellular immunology 1980;54(2):293-306.
1980: D T Notter; P L Grossman; STEVEN ROSENBERG; J S Remington
Infections in patients with Hodgkin's disease: a clinical study of 300 consecutive adult patients.
Reviews of infectious diseases 1980;2(5):761-800.
1980: C A Seipp; Alfred E Chang; D J Shiling; STEVEN ROSENBERG
In search of an effective antiemetic: a nusring staff participates in marijuana research.
Cancer nursing 1980;3(4):271-6.
1980: I Yron; T A Wood; P J Spiess; STEVEN ROSENBERG
In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
Journal of immunology (Baltimore, Md. : 1950) 1980;125(1):238-45.
1980: STEVEN ROSENBERG; P E Lipsky
The role of monocyte factors in the differentiation of immunoglobulin secreting cells from human peripheral blood B cells.
Journal of immunology (Baltimore, Md. : 1950) 1980;125(1):232-7.
1980: M T Lotze; J L Strausser; STEVEN ROSENBERG
In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(6):2972-8.
1980: STEVEN ROSENBERG
Hodgkin's disease: current status and future challenges.
Seminars in oncology 1980;7(2):212-4.
1980: D J Mathisen; STEVEN ROSENBERG
The in vivo distribution of transferred syngeneic, allogeneic, and xenogeneic lymphoid cells: implication for the adoptive immunotherapy of tumors.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(5):2295-300.
1980: D J Mathisen; STEVEN ROSENBERG
Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells.
Transplantation 1980;29(4):347-9.
1980: H F Sears; R Simon; STEVEN ROSENBERG
Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy.
Cancer treatment reports 1980;64(4-5):589-97.
1980: M S Catapano; J M Brown; STEVEN ROSENBERG
Levels of cytotoxic reactivity to cultured normal skin fibroblasts in sera from normal and sarcoma-bearing patients.
Cancer research 1980;40(4):979-83.
1980: R Stern; J Wilczek; W P Thorpe; STEVEN ROSENBERG; G Cannon
Procollagens as markers for the cell of origin of human bone tumors.
Cancer research 1980;40(2):325-8.
1980: STEVEN ROSENBERG; S Schwarz; P J Spiess; J M Brown
In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF.
Journal of immunological methods 1980;33(4):337-50.
1979: Alfred E Chang; D J Shiling; R C Stillman; Nelson H Goldberg; C A Seipp; I Barofsky; R M Simon; STEVEN ROSENBERG
Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Annals of internal medicine 1979;91(6):819-24.
1979: H Wexler; STEVEN ROSENBERG
Pulmonary metastases from autochthonous 3-methylcholanthrene-induced murine tumors.
Journal of the National Cancer Institute 1979;63(6):1393-5.
1979: A M Levine; STEVEN ROSENBERG
Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis.
Cancer 1979;44(6):2291-3.
1979: STEVEN ROSENBERG
Current concepts in cancer: non-Hodgkin's lymphoma--selection of treatment on the basis of histologic type.
The New England journal of medicine 1979;301(17):924-8.
1979: eugene woltering; W P Thorpe; J K Reed; STEVEN ROSENBERG
Split thickness skin grafting of the plantar surface of the foot after wide excision of neoplasms of the skin.
Surgery, gynecology & obstetrics 1979;149(2):229-32.
1979: STEVEN ROSENBERG; S C Tondreau; P C Shoffner; C Hyatt; J M Brown; W Thorpe; W Sindelar
Serologic analysis of human tumor antigens. II. Reactivity of sera from eleven osetogenic sarcoma patients against autologous and allogeneic tumor cells.
Surgery 1979;86(2):258-65.
1979: M Ribas-Mundo; STEVEN ROSENBERG
The value of sequential bone marrow biopsy and laparotomy and splenectomy in a series of 200 consecutive untreated patients with non-Hodgkin's lymphoma.
European journal of cancer 1979;15(7):941-52.
1979: R L Kirkman; R B Colvin; M W Flye; G S Leight; STEVEN ROSENBERG; GEORGE WILLIAMS; D H Sachs
Transplantation in miniature swine. VI. Factors influencing survival of renal allografts.
Transplantation 1979;28(1):18-23.
1979: W P Thorpe; J J Reilly; STEVEN ROSENBERG
Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy.
Cancer 1979;43(6):2178-81.
1979: W P Thorpe; STEVEN ROSENBERG
Serologic analysis of human tumor antigens. I. Antisarcoma antibodies in the sera of patients with osteogenic sarcomas.
Journal of the National Cancer Institute 1979;62(5):1143-50.
1979: STEVEN ROSENBERG; P E Lipsky
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells.
Journal of immunology (Baltimore, Md. : 1950) 1979;122(3):926-31.
1979: Alfred E Chang; E G Schaner; D M Conkle; M W Flye; J L Doppman; STEVEN ROSENBERG
Evaluation of computed tomography in the detection of pulmonary metastases: a prospective study.
Cancer 1979;43(3):913-6.
1979: J M Brown; W P Thorpe; STEVEN ROSENBERG
A sensitive assay for the detection cytotoxic antibodies to mammalian cell surface antigens.
Journal of immunological methods 1979;30(1):23-35.
1979: W Thorpe; W Loeb; C Hyatt; STEVEN ROSENBERG
Alkaline phosphatase measurements of paired normal and osteosarcoma tissue culture lines obtained from the same patient.
Cancer research 1979;39(1):277-9.
1978: STEVEN ROSENBERG
The management of Hodgkin's disease.
The New England journal of medicine 1978;299(22):1246-7.
1978: STEVEN ROSENBERG; S Schwarz; P J Spiess
In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens.
Journal of immunology (Baltimore, Md. : 1950) 1978;121(5):1951-5.
1978: STEVEN ROSENBERG; P J Spiess; S Schwarz
In vitro growth of murine T cells. I. Production of factors necessary for T cell growth.
Journal of immunology (Baltimore, Md. : 1950) 1978;121(5):1946-50.
1978: H F Sears; S C Tondreau; STEVEN ROSENBERG
Advantages of cryopreserved lymphocytes for sequential evaluation of human immune competence. II. Mixed lymphocyte cultures and mononuclear cell subpopulations.
Journal of the National Cancer Institute 1978;61(4):1011-6.
1978: J L Strausser; STEVEN ROSENBERG
In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens.
Journal of immunology (Baltimore, Md. : 1950) 1978;121(4):1491-5.
1978: G S Leight; R Kirkman; B A Rasmusen; STEVEN ROSENBERG; D H Sachs; R Terrill; GEORGE WILLIAMS
Transplantation in miniature swine. III: effects of MSLA and A-O blood group matching on skin allograft survival.
Tissue antigens 1978;12(2):65-74.
1978: D N Breiter; R B Diasio; J P Neifeld; M L Roush; STEVEN ROSENBERG
Serum copper and zinc measurement in patients with osteogenic sarcoma.
Cancer 1978;42(2):598-602.
1978: D N Weingrad; STEVEN ROSENBERG
Early lymphatic spread of osteogenic and soft-tissue sarcomas.
Surgery 1978;84(2):231-40.
1978: STEVEN ROSENBERG; H Kent; J Costa; B L Webber; R Young; B Chabner; A R Baker; Murray F Brennan; P B Chretien; M H Cohen; E V deMoss; H F Sears; C Seipp; R Simon
Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas.
Surgery 1978;84(1):62-9.
1978: E G Schaner; Alfred E Chang; J L Doppman; D M Conkle; M W Flye; STEVEN ROSENBERG
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study.
AJR. American journal of roentgenology 1978;131(1):51-4.
1978: STEVEN ROSENBERG; C Seipp; H F Sears
Clinical and immunologic studies of disseminated BCG infection.
Cancer 1978;41(5):1771-80.
1978: J A Norton; N R Shulman; Laurence Corash; R L Smith; F Au; STEVEN ROSENBERG
Severe thrombocytopenia following intralesional BCG therapy.
Cancer 1978;41(3):820-6.
1978: V H Bramwell; P A Voûte; STEVEN ROSENBERG; HERBERT PINEDO
Adjuvant treatment of soft tissue sarcoma in children and adults.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1978;68():60-74.
1978: STEVEN ROSENBERG; G A Parker; W P Thorpe
Expression of oncofetal antigens by murine and human normal cells in tissue culture.
Israel journal of medical sciences 1978;14(1):98-104.
1978: Nelson H Goldberg; J L Romolo; E H Austin; J Drake; STEVEN ROSENBERG
Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate.
Cancer 1978;41(1):52-5.
1977: M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; STEVEN ROSENBERG
Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.
Annals of surgery 1977;186(5):635-42.
1977: K R Hande; J E Balow; J C Drake; STEVEN ROSENBERG; B A Chabner
Methotrexate and hemodialysis.
Annals of internal medicine 1977;87(4):495-6.
1977: R G Stoller; K R Hande; S A Jacobs; STEVEN ROSENBERG; B A Chabner
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
The New England journal of medicine 1977;297(12):630-4.
1977: W P Thorpe; G A Parker; STEVEN ROSENBERG
Expression of fetal antigens by normal human skin cells grown in tissue culture.
Journal of immunology (Baltimore, Md. : 1950) 1977;119(3):818-23.
1977: G A Parker; STEVEN ROSENBERG
Serologic identification of multiple tumor-associated antigens on murine sarcomas.
Journal of the National Cancer Institute 1977;58(5):1303-9.
1977: STEVEN ROSENBERG
Lysis of human normal and sarcoma cells in tissue culture by normal human serum: implications for experiments in human tumor immunology.
Journal of the National Cancer Institute 1977;58(5):1233-8.
1977: G A Parker; STEVEN ROSENBERG
Cross-reacting antigens in chemically induced sarcomas are fetal determinants.
Journal of immunology (Baltimore, Md. : 1950) 1977;118(5):1590-4.
1977: G S Leight; D H Sachs; G M Williams; STEVEN ROSENBERG
Transplantation in miniature swine.
Transplantation proceedings 1977;9(1):575-7.
1977: G A Parker; C Hyatt; STEVEN ROSENBERG
Normal adult murine cells in tissue culture express fetal antigens.
Transplantation 1977;23(2):161-3.
1977: H F Sears; STEVEN ROSENBERG
Advantages of cryoperserved lymphocytes for sequential evaluation of human immune competence. I. Mitogen stimulation.
Journal of the National Cancer Institute 1977;58(2):183-7.
1977: STEVEN ROSENBERG; W D Terry
Passive immunotherapy of cancer in animals and man.
Advances in cancer research 1977;25():323-88.
1977: STEVEN ROSENBERG; S Schwarz; H Anding; C Hyatt; G M Williams
Comparison of multiple assays for detecting human antibodies directed against surface antigens on normal and malignant human tissue culture cells.
Journal of immunological methods 1977;17(3-4):225-39.
1976: STEVEN ROSENBERG; H J Rapp
Intralesional immunotherapy of melanoma with BCG.
The Medical clinics of North America 1976;60(3):419-30.
1976: J C Rosenberg; K Lysz; A Strefling; STEVEN ROSENBERG
Steroid suppression of protein synthesis of activated human lymphocytes.
The Journal of surgical research 1976;20(3):255-60.
1976: STEVEN ROSENBERG
Surgical treatment of malignant melanoma.
Cancer treatment reports 1976;60(2):159-63.
1976: H F Sears; STEVEN ROSENBERG
Increased reliability of cellular immune assays with cryopreserved lymphocytes: studies in humans.
Surgical forum 1976;27(62):160-2.
1976: H Kim; R F Dorfman; STEVEN ROSENBERG
Pathology of malignant lymphomas in the liver: application in staging.
Progress in liver diseases 1976;5():683-98.
1975: M H Cohen; L Schour; E L Felix; A D Bernstein; P B Chretien; STEVEN ROSENBERG; A S Ketcham
Staging laparotomy in the treatment of metastatic melanoma of the lower extremities.
Annals of surgery 1975;182(6):710-4.
1975: J C Rosenberg; W A Colburn; P Brennan; K Lysz; Margarida Palutke; S S Stubbs; STEVEN ROSENBERG
In vitro effect of methylprednisolone on protein synthesis of activated canine thymus-derived lymphocytes.
Transplantation proceedings 1975;7(4):547-56.
1975: STEVEN ROSENBERG
Future prospects for immunotherapy.
Cancer 1975;36(2):821-4.
1974: R E Wilson; P Alexander; STEVEN ROSENBERG; R L Simmons
Horizons in tumor immunology. A seminar.
Archives of surgery (Chicago, Ill. : 1960) 1974;109(1):17-29.
1974: STEVEN ROSENBERG; S Schwarz
Murine autoantibodies to a cryptic membrane antigen; possible explanation for neuraminidase-induced increase in cell immunogenicity.
Journal of the National Cancer Institute 1974;52(4):1151-5.
1974: N FRANKLIN ADKINSON; STEVEN ROSENBERG; W D Terry
Early detection of lymphocyte stimulation and mixed lymphocyte interaction in man with a semimicro protein synthesis assay.
Journal of immunology (Baltimore, Md. : 1950) 1974;112(4):1426-34.
1973: M R Moore; S E Jones; J M Bull; L A William; STEVEN ROSENBERG
MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.
Cancer 1973;32(1):52-60.
1973: STEVEN ROSENBERG; P B Brigham
Problems with the leukocyte migration inhibition technique in the study of human tumor immunity.
National Cancer Institute monograph 1973;37():139-40.
1973: J A Coyne; H G Remold; STEVEN ROSENBERG; J R David
Guinea pig lymphotoxin (LT). II. Physicochemical properties of LT produced by lymphocytes stimulated with antigen or concanavalin A: its differentiation from migration-inhibitory factor (MIF).
Journal of immunology (Baltimore, Md. : 1950) 1973;110(6):1630-7.
1973: STEVEN ROSENBERG; M Henrichon; J A Coyne; J R David
Guinea pig lymphotoxin (LT). I. In vitro studies of LT produced in response to antigen stimulation of lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1973;110(6):1623-9.
1973: STEVEN ROSENBERG
A rare type of Hodgkin's disease.
The New England journal of medicine 1973;288(15):789-90.
1973: D H Lavrin; STEVEN ROSENBERG; R J Connor; W D Terry
Immunoprophylaxis of methylcholanthrene-induced tumors in mice with Bacillus Calmette-Guérin and methanol-extracted residue.
Cancer research 1973;33(3):472-7.
1973: B Schechter; STEVEN ROSENBERG; Ronald Levy; S Ficker; W D Terry
Early evaluation of mixed leukocyte interactions in mice and guinea pigs using measurements of protein synthesis.
Cellular immunology 1973;6(2):261-72.
1972: S S Donaldson; M R Moore; STEVEN ROSENBERG; K L Vosti
Characterization of postsplenectomy bacteremia among patients with and without lymphoma.
The New England journal of medicine 1972;287(2):69-71.
1972: STEVEN ROSENBERG; B A Plocinik; G N Rogentine
"Unmasking" of human lymphoid cell heteroantigens by neuraminidase treatment.
Journal of the National Cancer Institute 1972;48(5):1271-6.
1972: STEVEN ROSENBERG; A B Einstein
Sialic acids on the plasma membrane of cultured human lymphoid cells. Chemical aspects and biosynthesis.
The Journal of cell biology 1972;53(2):466-73.
1972: STEVEN ROSENBERG; Ronald Levy
Synthesis of nuclear-associated proteins by lymphocytes within minutes after contact with phytohemagglutinin.
Journal of immunology (Baltimore, Md. : 1950) 1972;108(4):1105-9.
1972: STEVEN ROSENBERG; Ronald Levy
A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis.
Journal of immunology (Baltimore, Md. : 1950) 1972;108(4):1080-7.
1972: Ronald Levy; STEVEN ROSENBERG
The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen.
Journal of immunology (Baltimore, Md. : 1950) 1972;108(4):1073-9.
1972: STEVEN ROSENBERG; E Fox; W H Churchill
Spontaneous regression of hepatic metastases from gastric carcinoma.
Cancer 1972;29(2):472-4.
1971: STEVEN ROSENBERG; M Boiron; V T DeVita; R E Johnson; B J Lee; J E Ultmann; Manuel Viamonte
Report of the Committee on Hodgkin's Disease Staging Procedures.
Cancer research 1971;31(11):1862-3.
1971: STEVEN ROSENBERG
A critique of the value of laparotomy and splenectomy in the evaluation of patients with Hodgkin's disease.
Cancer research 1971;31(11):1737-40.
1971: STEVEN ROSENBERG
Hodgkin's disease of the bone marrow.
Cancer research 1971;31(11):1733-6.
1970: STEVEN ROSENBERG; J R David
Inhibition of leukocyte migration: an evaluation of this in vitro assay of delayed hypersensitivity in man to a soluble antigen.
Journal of immunology (Baltimore, Md. : 1950) 1970;105(6):1147-52.
1969: STEVEN ROSENBERG; G Guidotti
Fractionation of the protein components of human erythrocyte membranes.
The Journal of biological chemistry 1969;244(19):5118-24.
1968: STEVEN ROSENBERG; J Richard McIntosh
Erythrocyte membranes: effects on sonication.
Biochimica et biophysica acta 1968;163(3):285-9.
1965: STEVEN ROSENBERG; D K BRIEF; J M KINNEY; M G HERRERA; R E WILSON; F D MOORE
THE SYNDROME OF DEHYDRATION, COMA AND SEVERE HYPERGLYCEMIA WITHOUT KETOSIS IN PATIENTS CONVALESCING FROM BURNS.
The New England journal of medicine 1965;272():931-8.